Composition for prevention or control of plant diseases

The new Penicillium chrysogenum strain lnPP-2 and its AFPs provide a broad-spectrum solution for controlling phytopathogenic fungi and oomycetes, addressing the limitations of existing antifungal agents by effectively inhibiting disease growth and maintaining stability, thus enhancing agricultural sustainability.

WO2026234301A1PCT designated stage Publication Date: 2026-11-12INNOVPLANTPROTECT ASSOCIAÇÃO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063686
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-11
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a pressing need for broader spectrum antifungal agents to effectively prevent or control plant diseases caused by a wide range of phytopathogenic fungi and oomycetes, as existing solutions are limited in efficacy and environmental impact.

Method used

The use of a new strain of Penicillium chrysogenum (lnPP-2) and its antifungal proteins (AFPs) derived from a filtrate, which exhibit broad-spectrum in vitro growth inhibition against various phytopathogenic fungi and oomycetes, including Botrytis cinerea, Sclerotinia trifoliorum, and Pythium ultimum, while maintaining stability at extreme temperatures.

Benefits of technology

The filtrate and AFPs from P. chrysogenum lnPP-2 demonstrate high efficacy in preventing or controlling plant diseases, showing significant growth inhibition and disease symptom reduction in detached leaves and fruits, with stability across varying temperatures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000074_0001
    Figure IMGF000074_0001
  • Figure IMGF000044_0001_TABLE
    Figure IMGF000044_0001_TABLE
  • Figure IMGF000070_0001_TABLE
    Figure IMGF000070_0001_TABLE
Patent Text Reader

Abstract

The present disclosure relates to a strain of the fungi Penicillium chrysogenum, filtrates obtained from said strain, as well as antifungal proteins (AFPs) obtained from whole filtrate, their uses, formulations and methods for prevention or control of plant diseases caused by phytopathogenic fungi.
Need to check novelty before this filing date? Find Prior Art

Description

D E S C R I P T I O NCOMPOSITION FOR PREVENTION OR CONTROL OF PLANT DISEASES TECHNICAL FIELD

[0001] The present disclosure relates to the field of biological plant protection agents (BPPAs), more specifically to an antifungal filtrate obtained from a new strain of the fungus Penicillium chrysogenum, as well as antifungal proteins (AFPs) obtained from aforementioned filtrate, their uses, formulations and methods for prevention or control of plant diseases caused by phytopathogenic fungi and oomycetes.BACKGROUND

[0002] Agriculture involves the cultivation of plants for food, biofuels and raw materials. Crops are endangered by pests and diseases as well as decreasing soil quality and abiotic stresses, which can all drastically reduce harvest yields. Pesticides are substances that can repel, eradicate, or mitigate pests and diseases. According to the Food and Agriculture Organisation of the United Nations, four million tonnes of chemical-based pesticides were used globally in 2018, causing negative impact on soil, air and water quality as well as affecting non-target organisms.

[0003] The agricultural sector is also confronted with the concomitant challenge of increasing crop yields to feed the growing global population and increase the use efficiency of valuable resources while reducing the environmental impact on ecosystems and human health. In recent years, several technological innovations have been proposed to enhance the sustainability of agricultural production systems, through a significant reduction of synthetic agrochemicals like pesticides and fertilisers via replacement by innovative biological plant protection agents (BPPAs).

[0004] BPPAs offer targeted and environmentally friendly solutions to management of plant diseases. They are often part of integrated pest management (IPM) strategies, which aim to minimise the use of chemical pesticides while maintaining healthy crops and ecosystem balance. BPPAs can be categorised into various types, including beneficial fungi, amongst others.

[0005] In particular, the prevention and control of plant diseases caused by phytopathogenic fungi and oomycetes represents an increasingly significant challenge for agriculture. The constant emergence of fungicide-resistant strains emphasises the urgent need for development of improved antifungal agents with alternative mechanisms of action and broader activity spectra to those currently in use.

[0006] Indeed, antifungal proteins (AFPs) secreted by certain filamentous fungi have been proposed as promising candidates for the development of novel antifungal agents to prevent or control certain plantdiseases. AFPs are low molecular weight, cationic, cysteine-rich proteins (CRPs) that are stabilised by multiple disulphide bridges. AFPS are usually secreted in considerable concentrations by filamentous ascomycetes, mainly from the genera Penicillium, Aspergillus and Trichoderma, and have been shown to possess potent antifungal activity against other phytopathogenic fungi. Filamentous fungi are also capable of secreting secondary metabolites and other biomolecules which may be responsible for, or at least contribute to, the overall antifungal activity.

[0007] It is increasingly clear that fungi can generate a complex repertoire of biomolecules that may provide access to new generations of antifungal agents. Indeed, several antifungal agents originating from the Penicillium genera have been proposed in the literature as ecologically safe antifungal agents for prevention or control of plant diseases caused by phytopathogenic fungi (Kaiserer, 2003; Garrigues, 2017; Bugeda, 2020; Karpova, 2021).

[0008] However, there is still a requirement for broader spectrum antifungal agents for prevention or control of plant diseases caused by a wide range of phytopathogenic fungi and oomycetes.

[0009] This evidence, taken together, clearly indicates that there exists a pressing urgency for efficacious, environmentally benign, sustainable and economically viable antifungal solutions.

[0010] Document W02020005845A1 relates to synthetic compositions comprising a plant element and at least one fungal endophyte, which is capable of improving plant tolerance to biotic stress as compared to a reference plant element. However, the document is silent on a P. chrysogenum strain as described in the present disclosure.

[0011] Document WO2016210238 relates to methods and compositions for providing a benefit to a plant, namely soybean and maize plants, by associating the plant with a beneficial endophyte of the genus Penicillium. However, the document is silent on a P. chrysogenum strain as described in the present disclosure.

[0012] These facts are disclosed in order to illustrate the technical problem addressed by the present disclosure.GENERAL DESCRIPTION

[0013] The present disclosure relates to a filtrate from a new strain of the fungus P. chrysogenum , and antifungal proteins (AFPs) obtained from said filtrate, their uses, formulations and methods for prevention or control of plant diseases caused by phytopathogenic fungi and oomycetes.

[0014] The present disclosure also relates to filtrates and AFPs obtained from heterologous expression systems such as, for example, Pichia pastoris, and their uses, formulations and methods for prevention or control of plant diseases caused by phytopathogenic fungi.

[0015] In particular, the present disclosure relates to an isolated strain of Penicillium chrysogenum (codename lnPP-2), with the deposit with number MUM-P 26.03 received on 8thmay 2026 at the Micoteca da Universidade do Minho (MUM), placed at Centre of Biological Engineering, University of Minho, Campus de Gualtar, Braga - Portugal.

[0016] In an embodiment, the disclosed antifungal agents were obtained from the disclosed lnPP-2 strain. Surprisingly, the obtained antifungal agents are highly efficacious against plant disease-causing phytopathogenic fungi and oomycetes. In an embodiment, the antifungal agents were obtained in the form of filtrates. In a further embodiment, the antifungal agents are AFPs purified from said filtrates.

[0017] The disclosed strain of P. chrysogenum lnPP-2 was isolated as an air-borne contaminant in the Alto Alentejo region of Portugal. To genetically characterise the new strain of P. chrysogenum lnPP-2, whole genome sequencing was performed, the genome was assembled, and the two most closely related strains were found to have the NCBI RefSeq assembly codes GCF_028827035.1 and GCA_028826945.1.

[0018] It has since been surprisingly found that the filtrates and AFPs from P. chrysogenum lnPP-2 possess very broad spectrum in vitro growth inhibition of phytopathogenic fungi including, but not limited to, Botrytis cinerea, Sclerotinia trifoliorum, Penicillium expansum, Rosellinia necatrix, Fusarium oxysporum, Fusarium graminearum, Magnaporthe oryzae, Colletotrichum acutatum, Colletotrichum fioriniae, Colletotrichum nymphaeae, Stemphylium vesicarium, Alternaria brassicicola, Diaporthe amygdali, and Verticillium dahlia, as well as oomycetes, including, but not limited to, Pythium ultimum and Phytophthora cinnamomi. More surprisingly, it has been found that the filtrate from P. chrysogenum lnPP-2 does not demonstrate antifungal properties against beneficial fungi such as Mortierella elongata. Even more surprisingly, it has been found that the filtrate and AFPs from P. chrysogenum lnPP-2 display antifungal activity in detached leaf or fruit assays against phytopathogenic fungi.

[0019] In an embodiment for better results, the disclosed filtrates or AFPs may be used for the prevention or control of plant diseases caused by phytopathogenic fungi and oomycetes.

[0020] In an embodiment for better results, the AFPs contained in the filtrates and the purified AFPs have a molecular weight below 50 KDa, preferably below 30 KDa, even more preferably below 20 KDa and most preferably between 3 KDa and 15 KDa.

[0021] In an embodiment for better results, the filtrates or AFPs present excellent stability even when exposed to extreme temperatures, thereby maintaining their antifungal activities.

[0022] The lnPP-2 P. chrysogenum and some of the AFPs contained in the filtrate have been characterised as follows:> SEQ ID No 1 - Penicillium chrysogenum lnPP-2 ITS sequence:CTGGGTCACCTCCCACCCGTGTTTATTTTACCTTGTTGCTTCGGCGGGCCCGCCTTAACTGGCCGCCGGGGGGCTTA CGCCCCCGGGCCCGCGCCCGCCGAAGACACCCTCGAACTCTGTCTGAAGATTGTAGTCTGAGTGAAAATATAAATT ATTTAAAACTTTCAACAACGGATCTCTTGGTTCCGGCATCGATGAAGAACGCAGCGAAATGCGATACGTAATGTGA ATTGCAAATTCAGTGAATCATCGAGTCTTTGAACGCACATTGCGCCCCCTGGTATTCCGGGGGGCATGCCTGTCCG AGCGTCATTGCTGCCCTCAAGCACGGCTTGTGTGTTGGGCCCCGTCCTCCGATCCCGGGGGACGGGCCCGAAAGG CAGCGGCGGCACCGCGTCCGGTCCTCGAGCGTATGGGGCTTTGTCACCCGCTCTGTAGGCCCGGCCGGCGCTTGC CGATCAACCCAAATTTTTATCCAGGTTGACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAATAAG CGGAGGAA;> SEQ ID No 2 - Penicillium chrysogenum lnPP-2 complete beta-tubulin gene sequence:ATGCGTGAGATTGTACGTGATCCCCTCCAGACGCGTCTTTTGTTTTCATATGGCCCCTGAGCCACGACCCCACTCCC AACAGATCTTTTGCTAACTTGCTCTAGGTTCACCTCCAAACCGGCCAGTGTGTAAGTTCGACATGGAACATTCTTGG AAACATTCTTCGATGCGTGGGACTAAACTGGAATTGGGTTATAGGGTAACCAAATTGGTGCCGCTTTCTGGTAAGT CTCGGAGCTTTTTTTTCGCGTTGGGTATCAATTGACAAGTTGCTAACTGGATTACAGGCAAACCATCTCTGGCGAG CACGGTCTCGATGGCGATGGACAGTAAGTTTAACAGTGATGGGGATTCTGGTGGATCACACGTCTGATATCTTGC TAGGTACAATGGTACCTCCGACCTCCAGCTCGAGCGTATGAACGTCTACTTCAACCATGTGAGTACAATGACTGGG AATCTTAATTGTGCATCATCTGATCGGGCGTTTTTCTTTGACAATCTAGGCCAGCGGTGACAAGTACGTTCCCCGTG CCGTTCTGGTCGATTTGGAGCCCGGTACCATGGACGCTGTCCGCTCCGGTCCCTTCGGCAAGCTTTTCCGCCCCGA CAACTTCGTCTTCGGTCAGTCCGGTGCTGGTAACAACTGGGCTAAGGGTCACTACACTGAGGGTGCCGAGCTTGTT GACCAGGTCCTCGATGTCGTCCGCCGTGAGGCCGAGGGCTGTGACTGCCTCCAGGGTTTCCAGATCACCCACTCCC TGGGTGGTGGTACCGGTGCCGGTATGGGTACACTCCTGATCTCCAAGATCCGTGAGGAGTTCCCCGACCGTATGA TGGCCACTTTCTCCGTCGTCCCCTCCCCCAAGGTCTCCGACACCGTTGTTGAGCCTTACAACGCTACCCTCTCCGTCC ACCAGCTTGTTGAGCACTCTGACGAGACTTTCTGTATCGATAACGAGGTATGAAACGCGGGGAAATACTGACGTG AAGAATACTGACAATATTAGGCTCTCTACGACATTTGCATGCGTACCCTCAAGCTCCCCCAGCCTTCCTACGGTGAC CTGAACCACCTCGTCTCCGCCGTCATGTCCGGTGTGACCACCTCCCTTCGTTTCCCCGGTCAGCTCAACTCCGATCTT CGCAAGCTCGCCGTCAACATGGTTCCCTTCCCTCGTCTGCACTTCTTCATGGTCGGCTTCGCTCCCCTGACCAGCCG TGGTGGCTACTCTTACCGCCAGGTCAACGTCCCCGAGTTGACCCAGCAGATGTTCGACCCCAAGAACATGATGGCT GCCTCCGACTTCCGTAATGGCCGCTACCTCACTTGCTCCGCTCTGTTCCGCGGTAAGGTCTCCATGAAGGAGGTTG AGGACCAGATGCGCAACATCCAGAACAAGAACCAGAGCTACTTCGTTGAGTGGATCCCCAACAACGTCCAGACCG CTCTGTGCTCCGTTCCCCCCCGTGGCCTCAAGATGTCTTCCACCTTCGTCGGTAACTCGACTTCCATCCAGGAGCTCT TCAAGCGTGTCGGCGACCAGTTCACTGCCATGTTCCGTCGCAAGGCTTTCTTGCACTGGTACACTGGTGAGGGTAT GGACGAGATGGAGTTCACTGAGGCTGAGAGCAACATGAACGATCTTGTCTCCGAGTACCAGCAATACCAGGAGG CCTCCGTCTCCGAGGGCGAGGAGGAGTAGTAAGGATTCCCCACATCACCCGGCTTTCGAATATATCGACTAACGA ATTCTCCCCCTATTTTTAGCCTCGCTGAGGACATTGTTGACGAGGAGGTTTAA;> SEQ ID No 3 - Penicillium chrysogenum lnPP-2 PafB protein sequence (UniProt: A0A167QQK7, accessed on 08 / 05 / 2026):MHITSIAIVFFAAMGAVASPIATESDDLDARDVQLSKFGGECSLKHNTCTYLKGGKNHVVNCGSAANKKCKSDRHHCE YDEHHKRVDCQTPV> SEQ ID No 4 - Penicillium chrysogenum lnPP-2 PafC protein sequence (UniProt: A0A167U5W7 accessed on 08 / 05 / 2026):MKVTALLFTLMAATAVSASVLDTRDTCGGGYGVDQRRTNSPCQASNGDRHFCGCDRTGIVECKGGKWTEIQDCGGA SCRGVSQGGARC> SEQ ID No 5 - Penicillium chrysogenum lnPP-2 PafD protein sequence (UniProt: A0A167RZL7 accessed on 08 / 05 / 2026):MKLLMITTLLASLLVSTDATVVKAYKGTACKKDNYIGSVSACGSTGLSQNYKVQSLSLNFQKATASFYQQKPDRNGNCV GPRISKNSDQTCVKLPTGWDRFGCVKIHGGTC

[0023] In an embodiment for better results, the filtrate or AFPs may be used, for example, but not limited to, the prevention or control of diseases in tomato, vine, rice and Persian clover plants.

[0024] In an embodiment for better results, the filtrate or AFPs may be used, for example, but not limited to, prevention or control of diseases caused by phytopathogenic fungi and oomycetes of the genera Botrytis spp. and Pythium spp., respectively, amongst others.

[0025] In an embodiment for better results, the filtrate or AFPs may be used for the prevention or control of post-harvest decay in fruit caused by phytopathogenic fungi.

[0026] In an embodiment for better results, the filtrate or AFPs may be used for the prevention or control of diseases caused by phytopathogenic fungi or oomycetes.

[0027] In an embodiment for better results, the filtrate or AFPs are applied by spraying, irrigation or dipping.

[0028] Another aspect of the present disclosure relates to a formulation for prevention or control of plant diseases caused by phytopathogenic fungi and oomycetes comprising an effective amount of the disclosed filtrate or AFPs, optionally in the presence of a suitable additive.

[0029] In another embodiment for better results, the suitable additive is selected from a list consisting of: a carrier, a solvent, a buffer, a stabiliser, a preservative, an excipient, a surfactant, an adhesion agent, a drying agent, an emulsifier, an osmoprotectant, a sun protectant, a wetting agent, amino acids, antioxidants, chelating agents, biopolymers, sugars or biosurfactants, or mixtures thereof.

[0030] In an embodiment for better results, the biopolymer or carrier is alginate, chitosan, ulvan, fucoidan, carrageenan, xanthan gum, gellan gum, guar gum, gelatin, gum arabic, lignin, starch,maltodextrin, dextrin, cyclodextrin, dextran, zein, protamine sulphate, lecithin, gelatin, methacrylate-modified lignin, methacrylated gellan gum, polyvinyl alcohol, low density polyethylene, poly(e-caprolactone), polyethylene glycol, poly(lactic-co-glycolic acid), poly-L-lysine, in their native or modified forms (derivatives), applied individually or in combinations thereof.

[0031] In an embodiment for better results, the formulation may further comprise an agriculturally acceptable compound; preferably, the agriculturally acceptable compound is selected from: plant strengtheners, other biostimulants, nutrients, fertilisers, vitamins, minerals; or mixtures thereof.

[0032] In an embodiment for better results, the formulation may further comprise a BPPA, such as, but not limited to, an essential oil.

[0033] In an embodiment for better results, the formulation comprises an effective amount of the filtrate (0.5 - 60 mg / mL) or AFPs (20 - 80 pg / mL) and additives.

[0034] In an embodiment for better results, the formulation is in the form of a liquid, suspension concentrate, wettable powder, granules, flowables, macroencapsulations, microencapsulations or nanoencapsulations.

[0035] In certain embodiments, the composition may be formulated as a wettable powder. The term "wettable powder" refers to a substantially dry, finely divided particulate formulation capable of being dispersed or suspended in water prior to application. Wettable powder formulations may comprise the filtrate or encapsulated filtrate in combination with one or more carriers, dispersants, wetting agents, stabilizers, or other formulation auxiliaries. Such formulations may facilitate storage stability, ease of handling, and homogeneous application.

[0036] In certain embodiments, the composition may be formulated as granules. The term "granules" refers to particulate formulations comprising aggregated or compacted solid particles having a size greater than conventional powders. Granular formulations may comprise the filtrate or encapsulated filtrate together with one or more binders, fillers, carriers, stabilisers, or controlled-release agents. The granules may be produced by extrusion, agglomeration, spray granulation, fluid-bed processing, or other suitable techniques. Granular formulations may provide advantages including reduced dust formation, improved handling characteristics, controlled release properties, and enhanced storage stability.

[0037] In certain embodiments, the composition may be formulated as a flowable formulation. The term "flowable" refers to a liquid or semi-liquid suspension comprising finely divided solid particles dispersed within a continuous liquid phase. Flowable formulations may comprise the filtrate or encapsulated filtrate suspended or dispersed in water, oils, organic solvents, or combinations thereof, optionally together with suspending agents, dispersants, rheology modifiers, surfactants, preservatives, or stabilizers. Such formulations may enable uniform distribution, ease of dosing, compatibility with spraying or pumping equipment, and improved application performance.

[0038] The present disclosure relates to a Penicillium chrysogenum strain with the deposit number MUM-P 26.03 received on 8thmay 2026 at the Micoteca da Universidade do Minho.

[0039] In an embodiment, the Penicillium chrysogenum strain genome comprises and an ITS sequence comprising a sequence 90% identical to SEQ ID No 1; and a beta-tubulin gene sequence comprising a sequence 90% identical to SEQ ID No 2.

[0040] In an embodiment, the ITS sequence comprises a sequence 95% identical to SEQ ID No 1; preferably 96% identical, 97% identical, 98% identical, 99% identical or identical.

[0041] In an embodiment, the beta-tubulin gene sequence comprises a sequence 95% identical to SEQ ID No 2; preferably 96% identical, 97% identical, 98% identical, 99% identical or identical.

[0042] In an embodiment, the P. chrysogenum strain produces antifungal proteins, wherein the antifungal proteins comprise an amino acid sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, or SEQ ID No 5; preferably 96% identical, 97% identical, 98% identical, 99% identical or identical.

[0043] In an embodiment, the P. chrysogenum strain is for controlling and / or prevent plant or fruit diseases. In a further embodiment, the disease is an infection, in particular a fungal infection.

[0044] In an embodiment, the infection is caused by phytopathogenic fungi or oomycetes. In an embodiment for better results, the infection is caused by a phytopathogenic fungi selected from: Botrytis cinerea, Sclerotinia trifoliorum, Penicillium expansum, Rosellinia necatrix, Fusarium oxysporum, Fusarium graminearum, Magnaporthe oryzae, Colletotrichum acutatum, Colletotrichum fioriniae, Colletotrichum nymphaeae, Stemphylium vesicarium, Alternaria brassicicola, Diaporthe amygdali, Verticillium dahlia, or combinations thereof; and / or an oomycete selected from Pythium ultimum, Phytophthora cinnamomi, or combinations thereof.

[0045] In an embodiment, the infection is caused by B. cinerea.

[0046] In an embodiment, the disease is grey mould or root rot.

[0047] In an embodiment, the plant is tomato, vine, rice or Persian clover.

[0048] The present disclosure also relates to a filtrate obtained from the disclosed Penicillium chrysogenum strain for controlling and / or prevent plant or fruit diseases, wherein the filtrate comprises one or more extracellular bioactive compounds produced by the Penicillium chrysogenum strain; namely a cell-free filtrate obtained by culture decantation for separating fungal biomass from a fungal culture medium.

[0049] Filtrate refers to the liquid fraction recovered from a fungal culture medium after removal of fungal biomass, including fungal cells, hyphae, spores, and / or mycelial material. The filtrate maycomprise extracellular metabolites, secreted compounds, proteins, peptides, enzymes, volatile or nonvolatile compounds, secondary metabolites, and / or other bioactive substances produced by the fungus during cultivation. In some embodiments, the filtrate is a cell-free filtrate obtained by decantation, filtration, centrifugation, sterilisation, or combinations thereof.

[0050] In an embodiment, the filtrate is substantially free of fungal cells, mycelia, or insoluble material; preferably the filtrate is substantially cell-free; more preferably the filtrate is a cell-free filtrate.

[0051] For the scope and interpretation of the present disclosure, "substantially cell-free" refers to a filtrate containing less than 100 colony-forming units (CFU) per gram, preferably less than 50 CFU / g, more preferably less than 10 CFU / g. In an embodiment for better results, the filtrate is a cell-free filtrate, where no detectable viable P. chrysogenum cells are present in the filtrate under standard culturing conditions.

[0052] In an embodiment, the filtrate comprises proteins, peptides, polysaccharides, metabolites, glycoproteins, lipids, nucleic acids, or combinations thereof.

[0053] In an embodiment, the filtrate comprises one or more antifungal protein, preferably a protein with a molecular weight below 30 kDa, more preferably below 20 kDa, even more preferably a molecular weight that ranges from 3 kDa to 15 kDa.

[0054] In an embodiment, the filtrate comprises a protein selected from PafB (SEQ ID No 3), PafC (SEQ ID No 4), PafD (SEQ ID No 5), or mixtures thereof .

[0055] It is also disclosed a composition for controlling and / or prevent plant or fruit diseases comprising an effective amount of the disclosed Penicillium chrysogenum strain, and / or the disclosed filtrate, and / or an antifungal protein wherein the protein has a sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, or mixtures thereof; and a suitable additive.

[0056] In an embodiment, the suitable additive is selected from a list consisting of: a carrier, a solvent, a buffer, a stabiliser; a preservative, an excipient, a surfactant, an adhesion agent, a drying agent, an emulsifier, an osmoprotectant, a sun protectant, a wetting agent, a stabilizer, an amino acid, an antioxidant, a chelating agent, a biopolymer, a sugar, a biosurfactant, or mixtures thereof

[0057] In an embodiment, the amino acid is selected from phenylalanine, valine, tryptophan, isoleucine, methionine, leucine, L-lysine, histidine, serine, proline, glutamine, glycine, alanine, tyrosine, L-arginine, cysteine or mixtures thereof.

[0058] In an embodiment, the carrier is selected from alginate, chitosan, ulvan, fucoidan, carrageenan, xanthan gum, gellan gum, guar gum, gelatin, gum arabic, lignin, starch, maltodextrin, dextrin, cyclodextrin, dextran, zein, protamine sulphate, lecithin, gelatin, methacrylate-modified lignin,methacrylated gellan gum, polyvinyl alcohol, low density polyethylene, poly(e-caprolactone), polyethylene glycol, poly(lactic-co-glycolic acid), poly-L-lysine, their derivatives or combinations thereof; preferably chitosan, more preferably quaternized chitosan.

[0059] In an embodiment, the composition further comprises an agriculturally acceptable compound; preferably wherein the agriculturally acceptable compound is selected from: plant strengtheners, growth promoters, biostimulants, nutrients, fertilisers, vitamins, minerals; or mixtures thereof.

[0060] In an embodiment, the composition further comprises a biological plant protector agent selected from essential oils, microorganisms, such as Bacillus spp., Trichoderma spp., or Pseudomonas spp., extracts (preferably extracts from plants), fungi or other natural, semi-synthetic or synthetic biodegradable and non-toxic biomolecules, or mixtures thereof; preferably an essential oil.

[0061] In an embodiment, the composition comprises:10 - 99.5% (v / v) of the disclosed filtrate, preferably 10 - 50% (v / v), more preferably 15 - 30% (v / v); 12 - to 35 mM of an aminoacid, preferably 12.5 - to 20 mM of an aminoacid;preferably wherein the aminoacid is L-arginine, L-lysine, L-histidine, or combinations thereof.

[0062] In an embodiment, the composition comprises 0.5 to 60 mg / mL of the disclosed filtrate; preferably 30 - 60 mg / mL.

[0063] In an embodiment, the composition comprises 20 - 80 pg / mL of the antifungal protein; preferably, 25-60 pg / mL.

[0064] In an embodiment, the composition further comprises:0.1- 1% (w / v) of trehalose, preferably 0.2 to 0.5% (w / v);0.1 - 1% (w / v) of D-manitol, preferably 0.2 to 0.5% (w / v); and / or0.1 - 1% (w / v) of a carrier, preferably 0.2 to 0.5% (w / v), more preferably wherein the carrier is chitosan, in particular quaternized chitosan.

[0065] In an embodiment, the composition is in the form of a liquid, suspension concentrate, wettable powders, granules, flowables, microencapsulations or nanoencapsulations; preferably a wettable powder.

[0066] It is also disclosed the use of the disclosed Penicillium chrysogenum strain, and / or the disclosed filtrate and / or the disclosed composition as a biological plant protection agent.

[0067] It is also disclosed the use of one or more antifungal proteins as a biological plant protection agent, wherein the one or more antifungal proteins comprise an amino acid sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, or mixtures thereof; preferably 96% identical, 97% identical, 98% identical, 99% identical or identical. In an embodiment, the one or more antifungal proteins comprise at least two proteins having sequences selected from SEQ IDNo 3, SEQ ID No 4, and SEQ ID No 5; preferably the one or more antifungal proteins comprise proteins having the sequences SEQ ID No 3, SEQ ID No 4, and SEQ ID No 5. In an embodiment, the proteins are recombinant proteins.

[0068] In an embodiment, the plant is selected from tomato, vine, rice or Persian clover.

[0069] The present disclosure also relates to a method for control and / or prevent plant or fruit diseases, the method comprising applying an effective amount of the disclosed Penicillium chrysogenum strain, and / or the disclosed filtrate, and / or one or more antifungal proteins with a sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, or mixtures thereof, and / or the disclosed composition; preferably for control and / or prevent of plant diseases caused by phytopathogenic fungi and oomycetes.BRIEF DESCRIPTION OF THE DRAWINGS

[0070] The following figures provide preferred embodiments for illustrating the disclosure and should not be seen as limiting the scope of invention.

[0071] Figure 1. Embodiment of the phylogenetic tree representing the relationships between the P. chrysogenum genome of the disclosed isolate ("lnPP-2") and the publicly available genomes of 87 P. chrysogenum isolates (accessed and downloaded from the NCBI assembly database in April 2025), and Multidimensional Scaling plot (MDS plot, upper right corner).

[0072] Figure 2. Embodiment of the in vitro dual growth assay of Botrytis cinerea and Fusarium oxysporum with P. chrysogenum lnPP-2 in solid media. A- Growth of (i) B. cinerea; and (ii) B. cinerea in co-cultivation with P. chrysogenum for 9 days in potato dextrose agar (PDA) media. Growth of (iii) F. oxysporum; (iv) F. oxysporum in co-cultivation with P. chrysogenum lnPP-2 for 8 days in PDA media; B-Quantification of growth inhibition when in co-cultivation with P. chrysogenum lnPP-2, compared to the control (%).

[0073] Figure 3. Embodiment of the in vitro growth assay of different plant pathogenic fungi and oomycetes with P. chrysogenum lnPP-2 cell-free culture filtrate in solid media. A- In each panel, the left plate corresponds to the pathogen growth in the control PDA:King's B (PDA:KB) media (1:1; v / v) and the right plate to the pathogen growth in PDA:P. chrysogenum lnPP-2 cell-free culture media filtrate (1:1; v / v; P50). B- Quantification of the growth inhibition of different plant pathogenic fungi and oomycetes by P. chrysogenum lnPP-2 cell-free culture filtrate in solid media. Each grey and black column represents 2 and 5 days of co-cultivation in a 50 % (v / v) filtrate (P50), except for Verticillium dahliae for which the co-cultivation was extended to 5 and 9 days instead, to account for its slow growth. Error bars represent the standard deviation of the mean.

[0074] Figure 4. Embodiment of in vitro growth assay of Mortierella elongata, a broad-spectrum plant growth promoter, in the presence of P. chrysogenum lnPP-2 cell-free culture filtrate (P50) in solid media. A- M. elongata growth in control PDA:KB media (1:1; v / v); B- M. elongata growth in PDA media:P. chrysogenum lnPP-2 cell-free culture filtrate (1:1; v / v; P50). Images were taken 11 days post co-culture.

[0075] Figure 5. Embodiment of in vitro inhibition assay of Magnaporthe oryzae PR9-GFP grown with increasing concentrations of P. chrysogenum lnPP-2 cell-free culture filtrate (P5, PIO, P25 and P50) in liquid media and measured by means of fluorescence in a multi-well plate reader. Error bars represent the standard deviation of the mean.

[0076] Figure 6. Embodiment of the temperature stability of the P. chrysogenum lnPP-2 cell-free culture filtrate (P50) bioactivity as measured by filtrate exposure to different temperatures and assessment of the in vitro growth inhibition of Magnaporthe oryzae PR9. Error bars represent the standard deviation of the mean.

[0077] Figure 7. Embodiment of in vitro effect of P. chrysogenum lnPP-2 cell-free culture filtrate and filtrate fractions on Botrytis cinerea spore germination. Botrytis cinerea spore germination 7 h after incubation in a mixture of: i) King's B (KB) diluted 1:5 (v / v) in water as control; and ii) P. chrysogenum lnPP-2 cell-free culture filtrate diluted 1:1 (v / v; P50) in water; iii) Culture filtrate fraction smaller than 30 KDa diluted 1:1 (v / v; P50<30) in water; iv) Culture filtrate fraction bigger than 10 KDa diluted 1:1 (v / v; P50>10) in water; and v) Culture filtrate fraction smaller than 10 KDa diluted 1:1 (v / v; P50<10) in water.

[0078] Figure 8. Embodiment of the in vitro effect of P. chrysogenum lnPP-2 cell-free culture filtrate fractions on Botrytis cinerea appressorium formation. A- Botrytis cinerea appressorium formation 16 h after incubation in a mixture of: i) King's B diluted 1:5 (v / v) in water; ii) Culture filtrate diluted 1:1 (v / v; P50) in water; iii) Culture filtrate fraction smaller than 10 kDa diluted 1:1 (v / v; P50<10) in water (<10 kDa); iv) Culture filtrate fraction bigger than 10 kDa diluted 1:1 (v / v; P50>10) in water (>10 kDa). The top images correspond to bright-field, and the bottom images to GFP fluorescence; white arrows highlight appressorium formation. B- Quantification of B. cinerea appressorium formation upon 16 h incubation with different P. chrysogenum (lnPP-2) cell-free culture filtrate fractions.

[0079] Figure 9. Embodiment of in vitro growth inhibition of Botrytis cinerea in solid media containing P. chrysogenum lnPP-2 cell-free culture filtrate (P50) produced in minimal and surplus media. A- Botrytis cinerea growth in control conditions (without the P. chrysogenum lnPP-2 culture media filtrates): i) PDA : King's B media (1:1; v / v) control; ii) PDA : lx PcMM (Minimal media) (1:1, v / v) ; iii) PDA : 4xPcMM [Minimal media concentrated 4 times; (1:1; v / v)]. Botrytis cinerea growth in the presence of P. chrysogenum lnPP-2 culture media filtrates (1:1; v / v): iv) PDA: King's B media; v) PDA:lx PcMM; vi) PDA : 4xPcMM. Images were taken 3 days post-co-culture. B - Embodiment of the quantification of the in vitrogrowth inhibition of B. cinerea with P. chrysogenum lnPP-2 cell-free culture filtrate (P50) obtained from different media. Error bars represent the standard deviation of the mean.

[0080] Figure 10. Embodiment of the antifungal activity of P. chrysogenum lnPP-2 cell-free culture filtrate (P50) on Botrytis cinerea disease symptoms development in tomato leaves. A- Gray mould growth inhibition was observed on detached tomato leaves treated with: i) P. chrysogenum lnPP-2 culture filtrate diluted 1:1 (v / v; P50) with sterile water (Filtrate); and ii) KB media diluted 1:1 (v / v) with sterile water (King's B media); both conditions infected with B. cinerea (Bc-GFP; lxlO5spores / mL). Images were taken 4 days post-infection under UV light. B- Represents the respective quantification of the lesion areas calculated in ImageJ. Statistically significant differences were detected using one-way ANOVA and Tukey's post Hoc test. Different letters (a, b) indicate significant statistical differences (p<0.05, Tukey's test).

[0081] Figure 11. Embodiment of the antifungal activity of P. chrysogenum lnPP-2 cell-free culture filtrate on grey mould disease symptoms development on tomato fruits infected with Botrytis cinerea PF9 strain mycelium. Representative images of tomatoes treated with: i) King's B media control applied through dipping; ii) 100 % P. chrysogenum lnPP-2 cell-free culture filtrate (P100) applied through dipping; iii) King's B media control applied through dipping and infected with one plug of virulent B. cinerea 24 h later; iv) lnPP-2 cell-free culture filtrate (P100) and infected with one plug with virulent B. cinerea 24 h later. Images were taken 4 days post-infection.

[0082] Figure 12. Embodiment of the antifungal activity of P. chrysogenum lnPP-2 cell-free culture filtrate on Botrytis cinerea disease symptoms development on tomato fruits infected with spores. A-Representative images of tomatoes treated with: i) King's B media control through dipping; ii) King's B media control through dipping and infected with 1x10sspores / mL of virulent B. cinerea-GFP 24 h later; iii) 100 % P. chrysogenum lnPP-2 cell-free culture filtrate (P100) through dipping; iv) 100 % P. chrysogenum lnPP-2 cell-free culture filtrate (P100) through dipping and infected as above. Images were taken 4 days post-infection. Each treatment comprised eight technical replicates. B- Quantification of the lesion areas (cm2) calculated in ImageJ. Statistically significant differences were detected by one way ANOVA and Tukey Post-Hoc test. Different letters (a, b) indicate significant statistical differences (p<0.05, Tukey's test).

[0083] Figure 13. Embodiment of purification of AFP proteins from P. chrysogenum lnPP-2 cell-free culture filtrate through weak cation exchange resin. A- Coomassie Blue staining of a 15 % denaturing SDS-PAGE of eluted fractions (lanes 1-10) from batch purification of P. chrysogenum lnPP-2 cell-free culture filtrate on a weak cation exchange and eluted with a 10-100% (v / v) 1 M NaCI gradient. B-ClustalW alignment of full-length PafB (UniProt: A0A167QQK7 accessed on 08 / 05 / 2026), PafC (UniProt: A0A167U5W7 accessed on 08 / 05 / 2026) and PafD (UniProt: A0A167RZL7 accessed on 08 / 05 / 2026) proteins with the liquid chromatography-mass spectrometry (LC-MS, 90 min gradient) obtained peptidesequences. C- Abundance (loglO) of the LC-MS identified proteins purified from the pooled 4-6 fractions: PafB, PafC and PafD.

[0084] Figure 14. Embodiment of in vitro growth inhibition of Magnaporthe oryzae PR9-GFP grown for 96 hours with increasing concentrations of weak cation exchange purified Paf proteins (0.238 pg- 2.38 pg) from P. chrysogenum lnPP-2 cell-free culture filtrate, in liquid media, and measured by means of fluorescence in a plate reader. P. chrysogenum lnPP-2 cell-free culture filtrate at 50 % (v / v; P50) and P. chrysogenum lnPP-2 cell-free culture filtrate lower than 30 kDa at 50 % (v / v; P50< 30) were used as positive controls. Error bars represent the standard deviation of the mean.

[0085] Figure 15. Embodiment of the antifungal activity of P. chrysogenum lnPP-2 Paf proteins, isolated from the cell-free culture filtrate (P50), on Botrytis cinerea disease symptoms development on tomato fruits infected with spores. A- Representative images of tomatoes infected with 1x10sspores / mL of virulent B. cinerea Cl_7 strain and treated (al) once at 16 hours post-infection (hpi) and (a2) twice at 16 and 40 hpi. Treatments were as follows: i) MiliQ. water; ii) 1 / 5 King's B media diluted in water; iii) P. chrysogenum lnPP-2 cell-free culture filtrate at 50 % (v / v; P50); and iv) 50 pg / mL of P. chrysogenum lnPP-2 purified Paf proteins (mixture of PafB, C and D) isolated from the cell-free culture filtrate through a weak cation exchange resin. All treatments were supplemented with 0.05 % (v / v) Silwet. B-Quantification of the lesion areas (cm2) calculated in ImageJ, in the tomato fruits caused by infection of B. cinerea at 4 hpi, when fruits were treated i) once and ii) twice. Statistically significant differences were detected by one-way ANOVA and Tukey Post-Hoc test. Different letters (a, b) indicate significant statistical differences (p<0.05, Tukey's test). C- Quantification of the percentage of disease reduction when compared to the non-treated infected control. Analysis was performed at 4 days post-infection.

[0086] Figure 16. Embodiment of the low impact of P. chrysogenum lnPP-2 cell-free culture filtrate on the microbiome composition of soils from tomato-producing fields. Panel A- Number of observed taxa (alpha diversity) of fungi (i) and bacteria (ii). Panel B- Principal Coordinate Analysis of Bray-Curtis distances between samples (beta-diversity) for fungi (i) and bacteria (ii).

[0087] Figure 17. Embodiment of the in vitro growth inhibition of Botrytis cinerea by P. chrysogenum lnPP-2 cell-free culture filtrate formulated separately with increasing concentrations of the amino acids L-Arginine and L-Lysine at 3-9-12 and -19 days post inoculation (dpi). A- Representative images of control groups of B. cinerea growing on: i) PDA media: P. chrysogenum lnPP-2 cell-free culture filtrates at 1:1 and 1:0.5 (v / v), which corresponds to the filtrate at 50% and 25% (v / v; P50 and P25), respectively; ii) PDA media with increasing concentration of L- Arginine (12.5, 15 and 18 mM; A12.5, A15 and A18, respectively) or with increasing concentrations of L-Arginine and P. chrysogenum lnPP-2 cell-free culture filtrate at 20% (v / v; SP20A12.5, SP20A15, and SP20A18) at 3 (top plates) and 19 dpi (bottom plates); iii) PDA media with increasing concentration of L- Lysine (12.5, 15 and 18 mM; L12.5, L15 and L18, respectively) or with increasing concentrations of L-Lysine and P. chrysogenum lnPP-2 cell-free culturefiltrate at 20% (v / v; SP20L12.5, SP20L15, and SP20L18) at 3 (top plates) and 19 dpi (bottom plates). B-Quantification of the in vitro growth inhibition of B. cinerea at 3, 6, 12 and 19 dpi by formulated P. chrysogenum lnPP-2 cell-free culture filtrate. Error bars represent the standard deviation of the mean.

[0088] Figure 18. Embodiment of the mode of action of the formulation components and the P. chrysogenum lnPP-2 cell-free culture filtrate on Botrytis cinerea-GFP mycelial growth 72 h after coincubation and labelled with the red fluorescent intercalating agent propidium iodide (PI). B. cinerea-GFP: a) at time zero, spores in control media in brightfield; b) at 72 h, mycelium in control media in brightfield ; c) at 72 h, mycelium in control media with strong GFP signal in the green channel; d) at 72 h, mycelium in control media with weak PI signal in the red channel; e) at time zero, spores in 50% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v; P50); f) at 72 h, stressed mycelium in 50% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v; P50) in brightfield; g) at 72 h, stressed mycelium in 50% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v; P50) with weaker GFP signal compared to control in using green channel; h) at 72 h, mycelium in 50% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v; P50) with strong PI signal in the red channel; i) at time zero, spores in 25 mM L-arginine solution (A25) in brightfield; j) at 72 h, spores in 25 mM L-arginine solution (A25) showing weak germination in brightfield; I) at 72 h, spores 25 mM L-arginine solution (A25) showing GFP signal in all conidia expect the non-germinated; m) at 72 h, spores 25 mM L-arginine solution (A25) showing strong PI signal in the non-germinated conidia, n) at time zero, spores in 30% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v) and 25 mM L-arginine (SP30PA25) in brightfield; o) at 72 h, spores in 30% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v) and 25 mM L-arginine (SP30PA25) showing weak germination in brightfield; p) at 72 h, spores in 30% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v) and 25 mM L-arginine (SP30PA25) showing weak germination in green channel; q) at 72 h, spores in 30% P. chrysogenum lnPP-2 cell-free culture filtrate (v / v) and 25 mM L-arginine (SP30PA25) showing the beginning of a strong PI signal in the red channel. Images were taken using a green filter with peak emission at ~510 nm and a red filter with peak emission at ~617 nm.

[0089] Figure 19. Embodiment of the effectiveness of different formulated P. chrysogenum lnPP-2 cell-free culture filtrate in controlling the grey mould disease on tomato fruits caused by Botrytis cinerea. / -representative images of tomatoes treated with i) water before and 40 h post B. cinerea infection applied by spraying; ii) FWP_1 formulation, a wettable powder (WP) of filtrate spray-dried lnPP-2 with 25 mM L-arginine, 10 mM L-histidine, and 0.01% Tween 20 (v / v) and applied by spraying at 96.5 mg / mL of aqueous preparation (FWP_1); iii) FWP_2 formulation, a WP prepared by spray-drying of lnPP-2 cell-free culture filtrate with 25 mM L-arginine, 10 mM L-histidine, 0.1% Trehalose (w / v), 0.1 % D-mannitol (w / v), and 0.01% Tween 20 (v / v) and applied by spraying at 109 mg / mL of aqueous preparation (FWP_2); iv) a commercial product (Syngenta Switch®) applied by spraying at 1 g / L following the instructions of the manufacturer. B- Quantification of the lesion areas in mm2using image J software.Statistical analyses were performed based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test) with Kruskal-Wallis and Dunn's post hoc tests using R version 4.3.3.. The null hypothesis of equal means was rejected when the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. Different letters (a, b, and c) indicate significant statistical differences between groups.

[0090] Figure 20. Embodiment of the effectiveness of formulated P. chrysogenum lnPP-2 cell-free culture filtrate (FWP_3) in controlling the damping-off disease caused by Pythium ultimum on Persian clover seedlings. A - Representative experiments of i) non-infected Persian clover control irrigated with water before sowing; ii) Persian clover infection-control, i.e, Persian clover seeds sown into soil mixed with P. ut / imum-infected millet grains; iii) P. ultimum-infected soil treated with an lnPP-2 formulation, a WP prepared by spray-drying lnPP-2 filtrate with L-arginine (25 mM), L-histidine (10 mM), Trehalose (0.5% w / v), and D-mannitol (0.5% w / v) at 1.325 mg / mL before sowing Persian clover (FWP_3); iv) represents P. ut / imum-infected soil treated with a commercial product (Rival®) applied at 0.6 mL / L. B-Quantification of seedling Persian clover emergence fold increase upon lnPP-2 formulation (FWP_3) or Commercial product treatments under P. ultimum relative to the infection control (One-way Anova and Dunn's post hoc tests) with p values < 0.001. The data are displayed as box-and-whisker plots, wherein the boxes denote the interquartile range, the central line indicates the median, and an "X" represents the mean value of independent biological replicates. All data were standardised by dividing the mean value with the mean of the untreated infected control represented in the graph by a dashed horizontal line.; C- Quantification of the relative emergence of Persian clover grown in substrate infected with P. ultimum. The relative seed emergence was calculated as (emerged seedlings / total sown seeds) x 100, and seedling emergence efficacy was defined as the percentage increase relative to the control.

[0091] Figure 21. Embodiment of the effect of the lnPP-2 formulation (FWP_3) on the disease severity of the damping-off of Persian clover under Pythium ultimum infection as compared to a commercial product in semi-controlled open-field conditions after the first application of one preventive treatment before sowing, and another curative treatment one week after sowing. A- representation of the disease development of P. ultimum over the second, third, and fourth weeks post infection under the treatments; i: non-infected control, ii: untreated control infected with P. ultimum, iii: Pots infected with P. ultimum and treated with the formulation FWP_3, applied immediately before sowing and one week after sowing, iv: P. ultimum-infected substrate treated with a commercial product (Rival®) applied only once before sowing at 0.6 mL / L. B- represents the area under disease pressure curve calculated by integrating the assessment of two distinct characteristic symptoms of P. utlimum disease development: the hight of the plants, and the colour of the leaves. Statistical analyses were performed based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test) with one way ANOVA and Tukey's HSD post hoc tests using R version 4.3.3. The null hypothesis of equal means was rejectedwhen the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. Different letters (a, and b) indicate significant statistical differences between groups.

[0092] Figure 22. Embodiment of the effect of lnPP-2 formulation (FWP_3) on the fresh / dry weight increase of Persian clover under Pythium ultimum infection as compared to a commercial product (Rival®) in semi-controlled open-field conditions. lnPP-2 formulation FWP_3 was applied at the rate of 1.325 mg / mL of aqueous preparation immediately before sowing, and one week after sowing. The commercial product Rival® was applied once at sowing (0.6 mL / L). A- and C- Quantification of the shoot fresh and dry weights, respectively, of Persian clover grown in P. u / timum-infected substrate with significant differences between treatments as demonstrated by One-way Anova and Dunnett's posthoc tests with p values < 0.05. The data are displayed as box-and-whisker plots, wherein the boxes denote the interquartile range, the central line indicates the median, and an "X" represents the mean value of independent biological replicates. All data were standardised by dividing the mean value with the mean of the untreated infected control represented in the graph by a dashed horizontal line; B- and D-Quantification of total fresh and dry weights, respectively, which represent the increase of Persian clover plant biomass relative to the untreated infected control. The relative increase in weights was calculated by dividing the mean value of independent biological replicates of the treatment by the mean of the untreated infected control.

[0093] Figure 23. Embodiment of the effect of the lnPP-2 formulation (FWP_3) on alleviating the disease pressure of Persian clover plants under Pythium ultimum infection as compared to a commercial product (Rival®) in semi-controlled open-field conditions. A- Quantification of anthocyanin content (Stress Indicator) in Persian clover grown in P. ultimum -infected substrate and treated with lnPP-2 formulation (FWP_3The data are displayed as box-and-whisker plots, wherein the boxes denote the interquartile range, the central line indicates the median, and an "X" represents the mean value of independent biological replicates. All data were standardised by dividing the mean value with the mean of the untreated infected control represented in the graph by a dashed horizontal line. ; B- Relative anthocyanin content (stress Indicator) of Persian clover grown in P. ultimum -infected substrate as compared to the untreated infected control. The relative anthocyanin content was calculated as [(treatment - infected control) / infected control] x 100 and was defined as the percentage of reduction or increase relative to the infected control. C- Quantification of flavonol content (antioxidant indicator) in Persian clover grown in P. ultimum -infected substrate and treated with lnPP-2 formulation (FWP_3) in which high the flavonol levels were significantly higher (one way ANOVA and Dunnett's post hoc tests) than the untreated infected control and Rival®. This reflects plants with lower stress compared to the diseased and chemically treated plants. The data were evaluated and displayed as described above.; D -Relative flavonol content (antioxidant indicator) of Persian clover grown in P. ultimum -infectedsubstrate of plants treated with a wettable powder formulation of lnPP-2 filtrate (FWP_3) and applied at the rate of 1.325 mg / mL of aqueous preparation immediately before, and one week after sowing and with the commercial product Rival® which was applied once at sowing (concentration 0.6 mL / L). The relative flavonol content was evaluated as described above. E- Quantification of chlorophyll content index (photosynthetic activity indicator) in Persian clover grown in P. ultimum -infected substrate and treated with lnPP-2 formulation FWP_3 (Kruskal-Wallis and Dunn's post hoc tests). The data were evaluated and displayed as described above; E- Relative chlorophyll content index (photosynthetic activity indicator) of Persian clover grown in P. ultimum -infected substrate of plants treated with the formulation (FWP_3) applied at the rate of 1.325 mg / mL of aqueous preparation immediately before, and one week after sowing and with the commercial product Rival® which was applied once at sowing (concentration 0.6 mL / L). The relative chlorophyll content index content was evaluated and displayed as described above.

[0094] Figure 24. Embodiment of the effect of the formulated lnPP-2 cell-free culture filtrate (FWP_4 and FWP 4.1) on the prevention of black spot disease caused by Alternaria brassicicola on broccoli plants as compared to two commercial products. FWP_4 was applied at the concentration of 59 mg / mL. FWP_4.1 was applied at the concentration 85 mg / mL. A-Quantification of the treatment's efficacy, showing a significant reduction (One way ANOVA and Tukey's HSD post hoc tests) in disease observed with lnPP-2 formulation FWP_4 compared to the untreated infected control. The data are displayed as box-and-whisker plots, wherein the boxes denote the interquartile range, the central line indicates the median, and an "X" represents the mean value of independent biological replicates. All data were standardised by dividing the mean value with the mean of the untreated infected control represented in the graph by a dashed horizontal line. B- Quantification of the percentage of disease severity reduction compared with the untreated control calculated as [(treatment - infected control) / infected control] x 100 and. C- Quantification of the treatment efficacy of FWP_4.1 showing no significant difference between the lnPP-2 formulation and the two commercial products Ortiva Top® and Dagonis® in reducing disease symptoms caused by A. brassicicola as compared to the untreated infected control (One way ANOVA and Tukey's HSD post hoc tests). The data were evaluated and displayed as described above. D-Quantification of the percentage of disease severity reduction compared with the untreated control calculated as described above.

[0095] Figure 25. Embodiment of the effect of the formulated lnPP-2 cell-free culture filtrate (FWP_5) on the prevention of the rice blast disease symptoms caused by Magnaporthe oryzae on rice plants, as compared to a commercial reference product. lnPP-2 formulation FWP_5 was applied at the rate of 72 mg / mL (FWP_5). The commercial product is Amistar Top® (5mL / L). Both treatments were applied 24 h before infecting rice leaves with M. oryzae spores. A- Quantification of the treatment's efficacy by evaluating the mean disease coverage standardised by the mean of the infected control, represented inthe graph by a dashed horizontal line (One way ANOVA and Tukey's HSD post hoc tests). The data are displayed as box-and-whisker plots, wherein the boxes denote the interquartile range, the central line indicates the median, and an "X" represents the mean value of independent biological replicates.; B-Quantification of the percentage of disease severity reduction calculated as [(treatment - infected control) / infected control] x 100.DETAILED DESCRIPTION

[0096] The present disclosure relates to a strain of the fungi Penicillium chrysogenum, filtrates obtained from said strain, as well as antifungal proteins (AFPs) obtained from whole filtrate, their uses, formulations and methods for prevention or control of plant diseases caused by phytopathogenic fungi.

[0097] The present disclosure relates to a new strain of P. chrysogenum, the lnPP-2, to a broadspectrum antifungal filtrate and AFPs obtained from the disclosed P. chrysogenum lnPP-2. Formulations for prevention and / or control of plant diseases caused by phytopathogenic fungi and oomycetes, comprising applying an effective amount of said filtrate, AFP, or formulations are also disclosed. The use of the disclosed filtrate, AFPs or formulations to prevent or control plant diseases caused by phytopathogenic fungi and oomycetes and a method for applying an effective amount of the filtrate, AFPs or the compositions, are also disclosed.

[0098] In an embodiment, P. chrysogenum lnPP-2 can exert an antifungal effect through several mechanisms, including the release of AFPs and / or other metabolites endowed with antifungal properties.

[0099] In an embodiment, the formulations comprising the filtrate or AFPs may contain a solvent, water and / or an acceptable buffer.

[0100] In a preferred embodiment, the formulations comprising the filtrate or AFPs may contain additives which serve to: i) stabilise the filtrate or AFPs and allow application in the field via irrigation using contemporary agricultural equipment; ii) protect the filtrate or AFPs from premature degradation due to humidity, high and low temperatures and solar ultraviolet light exposure; iii) maintain the viability of the filtrate or AFPs over time; iv) control the release rate of filtrate or AFPs over time and v) exert synergistic effects with the filtrate that permit significant reduction of the concentration of the filtrates whilst maintaining high fungicidal activity.

[0101] Representative formulations of the compositions used in the assays described in Examples 2-13 and illustrated in Figures 3-25 are summarised in Table 1. These formulations are provided for illustrative purposes and do not limit the scope of the invention.Table 1: Codes, components, and concentrations of the formulation of P. chrysogenum lnPP-2 cell-free culture filtrate. All the mentioned treatments are aqueous preparations.P. chrysogenum Additive components and their respective concentrations Codes lnPP-2 cell-free L- L- L- D- Quaternized Trehaloseculture filtrate arginine Lysine histidine mannitol Chitosan (HTCC) P5 5% (v / v) - - - - - - PIO 10% (v / v) - - - - - - P20 20% (v / v) - - - - - - P25 25% (v / v) - - - - - - P30 30% (v / v) - - - - - - P50 50% (v / v) - - - - - - P100 100% (v / v) - - - - - - P50<30 50% (v / v), fraction - - - - - - <30 kDaP50<10 50% (v / v), fraction - - - - - - < 10 kDaA12.5 - 12.5 - - - - - mMA15 - 15 mM - - - - - A18 - 18 mM - - - - - A25 - 25 mM - - - - - L12.5 - - 12.5 - - - - mML15 - - 15 mM - - - - L18 - - 18 mM - - - - SP20A12.5 20% (v / v) 12.5 - - - - - mMSP20A15 20% (v / v) 15 mM - - - - - SP20A18 20% (v / v) 18 mM - - - - - SP30A25 30% (v / v) 25 mM - - - - - SP20L12.5 20% (v / v) - 12.5 - - - - mMSP20L15 20% (v / v) - 15 mM - - - - SP20L18 20% (v / v) - 18 mM - - - - Codes of the spray-dried formulationsFWP l 99.4% (v / v) 25 mM - 10 mM - - - FWP 2 99.2% (v / v) 25 mM - 10 mM 0.1% (w / v) 0.1% (w / v) - FWP 3 98.4% (v / v) 25 mM - 10 mM 0.5% (w / v) 0.5% (w / v) - FWP 4 98.7% (v / v) 25 mM - 10 mM 0.1% (w / v) 0.1% (w / v) 0.5% (w / v) FWP 4.1 98.9% (v / v) 25 mM - 10 mM - - 0.5% (w / v) FWP 5 97.4% (v / v) 25 mM - 10 mM 1% (w / v) 1% (w / v) - Legend: P: P. chrysogenum lnPP-2 cell-free culture filtrate; S: aqueous solution; WP: wettable powder; F:formulation; A: L-Arginine; L: L-Lysine

[0102] Said additives may comprise stabilisers, amino acids, antioxidants, chelating agents, biopolymers, sugars or biosurfactants, separately or in combination. Examples of amino acids include, but are not limited to, phenylalanine, valine, tryptophan, isoleucine, methionine, leucine, lysine, histidine, serine, proline, glutamine, glycine, alanine, tyrosine, arginine and cysteine. Particularly preferred amino acids include L-arginine and L-lysine.

[0103] Examples of biopolymers include, but are not limited to, alginate, chitosan, quaternized chitosan, ulvan, fucoidan, carrageenan, xanthan gum, gellan gum, guar gum, quaternized guar gum, starch, quaternized starch, gelatin, gum arabic, lignin, maltodextrin, dextrin, cyclodextrin, dextran, zein, protamine sulphate, lecithin, gelatin, methacrylate-modified lignin, methacrylated gellan gum, polyvinyl alcohol, low density polyethylene, poly(e-caprolactone), polyethylene glycol, poly(lactic-co-glycolic acid), poly-L-lysine, or combinations thereof.

[0104] For the scope and interpretation of the present disclosure, the term "quaternized polymer" refers to a polymer, including but not limited to chitosan, starch, cellulose, or derivatives thereof, which has been chemically modified to introduce quaternary ammonium functional groups, thereby imparting a permanent positive charge to the polymer backbone independent of the pH of the surrounding medium. Such modification may be achieved through substitution reactions on available functional groups of the polymer, resulting in enhanced solubility, cationic character, and affinity for negatively charged substances.

[0105] In embodiment, the sugar is selected from glucose, sucrose, lactose, maltose, trehalose, or combinations thereof.

[0106] In an embodiment, agriculturally acceptable compounds can be added to the compositions comprising the filtrate or AFPs in order to extend shelf-life and optimise the processability and physicochemical characteristics of the formulation. Such agriculturally acceptable compounds can include, but are not restricted to, plant strengtheners, other growth promoters, nutrients, wetting agents, drying agents, solvents, buffers, stabilisers, osmoprotectants, solar protectants, excipients, surfactants, adhesion agents, fertilisers, emulsifiers, vitamins, minerals, additives and / or preservatives, or combinations thereof.

[0107] In a further embodiment, in order to improve efficacy, onset and duration of action, the formulation comprising the filtrate or AFPs may be supplemented with at least one other BPPA, selected from essential oils, beneficial microorganisms, such as Bacillus spp., Trichoderma spp., or Pseudomonas spp., extracts from plants, microorganisms or fungi or other natural, semi-synthetic or synthetic biodegradable and non-toxic biomolecules, among others.

[0108] In another embodiment, the formulations comprising the filtrate or AFPs may be in the form of a liquid, concentrate, tablet, gel, pellet, wettable powder, granule or flowable, amongst others.

[0109] In a preferred embodiment, the formulation is in the form of macrocapsules (size > 1000 pm), microcapsules (size range 1-999 pm) or nanocapsules (size range 1-999 nm) wherein the filtrate or purified AFPs are initially retained within the interior of the capsule shell and released over time. The macrocapsules, microcapsules or nanocapsules may be prepared from one or more biodegradable, nontoxic materials that may be selected from natural-origin polymers, proteins or lipids, such as, but notlimited to, chitosan, alginate, ulvan, fucoidan, carrageenan, xanthan gum, gellan gum, guar gum, starch, gelatin, gum arabic, lignin, maltodextrin, dextrin, zein, protamine sulphate, dextrin or lecithin and / or their derivatives, or combinations thereof.

[0110] In another embodiment, the microcapsules or nanocapsules comprising the filtrate or AFPs may be prepared from one or more non-toxic, biodegradable synthetic or semi-synthetic materials such as, but not limited to, methacrylate-modified lignin, methacrylated gellan gum, polyvinyl alcohol, low-density polyethylene, poly(e-caprolactone), polyethylene glycol or poly(lactic-co-glycolic acid).

[0111] Through judicious choice of encapsulation material(s), variation of polymer concentration, crosslinking density, interior pore size, capsule size, shape and surface charge, it is possible to tune the loading capacity, entrapment efficiency and release kinetics of the entrapped filtrate or AFPs. Suitable techniques for microencapsulation include ionic gelation, spray-drying, and microfluidics, the latter being suitable also for nanoencapsulation. By optimising parameters such as air temperature, feed flow rates and so on, it is possible to fine-tune the physicochemical properties of the capsules, which can, if necessary, be further processed downstream by techniques such as ball milling and drying by conventional means or on a fluid-bed dryer.EXAMPLES

[0112] 1. Genetic characterisation ofP. chrysogenum lnPP-2.

[0113] P. chrysogenum lnPP-2 was grown on King's B (KB) agar media (20 g / L proteose peptone, 10 mL / L glycerol, 1.5 g / L K2HPO4, 1.5 g / L MgSO4.7H2O, 15 g / L agar) at 20 °C for 7 to 30 days. For genomic DNA extraction five mycelium plugs of P. chrysogenum lnPP-2 were grown in 200 mL of a defined medium (5 mL / L glycerol, 2 g / L Casamino acids (CAS number: 91079-40-2), 1.5 g / L K2HPO4, 1.5 g / L MgSO4.7H2O), for 7 days at 20 °C with 150 rpm agitation. At day 7, the culture broth was separated from the mycelium biomass firstly by passing it through a coffee filter and then a Whatman filter paper. The recovered mycelium was washed with double-distilled water, transferred to a mortar, ground in liquid nitrogen to a fine powder, and transferred into a 2 mL centrifuge tube. Seven hundred microliters of 2xCTAB buffer (Cetyltrimethylammonium bromide buffer), preheated at 65 °C, was added to the centrifuge tube, mixed, and incubated at 65 °C for 30 min with shaking every 10 min. The solution was centrifuged at 10,000 x g for 10 min, and the supernatant was transferred to a fresh 2 mL centrifuge tube. An equal volume of phenol:chloroform:isopropanol (25:24:1; v / v) was added, and the solution was incubated for 15 min in a rotary shaker at room temperature (RT). The solution was centrifuged for 10 min at 16.000 xg at RT, the supernatant was recovered, and the extraction was repeated two more times. To the final supernatant, 1 mL of chilled isopropanol was added, the solution was mixed and incubated overnight at -20 °C. The solution was centrifuged at 16,000 x g for 10 min at 4 °C, and the supernatant was discarded. The DNA pellet was air-dried, resuspended in 600 pL of lxTE (Tris-EDTA, pH 8), and RNAse (10 mg / mL, 6 pL to 600 pL TE) was added. The mixture was incubated at 37 °C for 30 minto 1 h. The DNA was reprecipitated using 60 pL of 3 M sodium acetate (pH 5.3) and 1 mL of chilled absolute ethanol (EtOH), then mixed and incubated for 10 min at -20 °C. The mixture was centrifuged at 16,000 x g for 10 min at RT; the supernatant was discarded, and the DNA pellet was washed with 1 mL of 70% (v / v) EtOH, then centrifuged at 16,000 x g for 2 min between washes. This step was repeated three times, and in the last wash, absolute EtOH was used instead. The pellets were air-dried inside a flow hood and resuspended in lxTE (pH 8, preheated to 58 °C). The resultant DNA was used for wholegenome sequencing. PacBio SMRTbell libraries were prepared using the PacBio SMRTBell prep kit 3.0 (PacBio, Menlo Park, CA) and loaded on the sequencer using the PacBio Sequel II Binding kit 3.2, according to the manufacturer's protocol. Sequencing was performed on a PacBio Sequel lie using PacBio HiFi mode. This generated 424068 reads, with an average size of 12519 bp. Genome assembly was performed with NextDenovo v2.5.2 using default parameters, with the following exceptions: read_type = hifi, genome_size = 32 m. The genome assemblies for 87 P. chrysogenum isolates were downloaded from the NCBI assembly database in April 2025. BUSCO v5.8.3 was then used to extract DNA sequences for a large set of single-copy homologous genes from these 87 genomes and the genome of the disclosed isolate. Phylogenetic analysis was partly carried out with the BUSCO Phylogenomics pipeline using default parameters, and a supported Maximum-Likelihood tree (Figure 1) was generated using the concatenated alignment matrix from the pipeline's output with IQ-TREE v2.4.0.. Succinctly, phylogenetic relationships were constructed from 3706 BUSCO gene families that were found to be complete, single-copy, and common in at least four isolates. BUSCO phylogenomics used Muscle and trimAI to align and trim the gene sequences and IQ-TREE to generate the final phylogenetic tree. The tree was visualised, and midpoint rooted using TreeViewer v2.2.0 The tree indicates that the disclosed P. chrysogenum isolate lnPP-2 belongs to a fully supported, distinct branch within a small clade of genomes that is distantly related to the majority of the P. chrysogenum available in the NCBI database. The aforementioned genomes were also compared at an Average Nucleotide Identity (ANI) threshold of 99.5 %, which is typically used to delineate fungal strains. The ANI comparisons were computed with dRep v3.6.1, and the embodiment of the genetic similarity of the genomes was shown in a MDS plot (Figure 1). This plot further highlights that the disclosed P. chrysogenum isolate lnPP-2, represents a distinct strain. Pencillium chrysogenum lnPP-2 was characterised as having the ITS sequence SEQ ID No 1 and the complete beta-tubulin sequence SEQ ID No 2.

[0114] For the scope and interpretation of the present disclosure it is defined that "room temperature" should be regarded as a temperature between 15-30 °C, preferably between 18-25 °C, more preferably between 20-22 °C.

[0115] A phylogenetic tree with P. chrysogenum lnPP-2 and the 87 publicly available P. chrysogenum genomes was generated, showing that disclosed P. chrysogenum lnPP-2 isolate belongs to a fullysupported, distinct branch within a small clade of genomes that is distantly related to the majority of the P. chrysogenum available in the NCBI database (Figure 1). Moreover, clustering the P. chrysogenum lnPP-2 and the 87 publicly available genomes at an ANI threshold of 99.5% (threshold typically used to delineate fungal strains) shows that P. chrysogenum lnPP-2 represents a distinct strain. The MDS plot depicted in Figure 1 further highlights the genetic distinctiveness of this isolate.

[0116] In an embodiment, identification and differentiation of Penicillium strains may be performed using molecular markers including the internal transcribed spacer (ITS) region and p-tubulin gene sequences. The ITS region is widely used for fungal taxonomic identification due to its combination of conserved and variable regions, enabling discrimination at the genus and species levels. The p-tubulin gene provides additional phylogenetic resolution and strain-level discrimination due to its higher sequence variability among closely related Penicillium isolates. Accordingly, comparative analysis of ITS and p-tubulin nucleotide sequences may be used to distinguish the disclosed strain from other Penicillium strains and to confirm its taxonomic identity.

[0117] 2. In vitro inhibition of phytopathogenic fungi and oomycetes growth by P. chrysogenum lnPP-2

[0118] The inhibitory effect of P. chrysogenum lnPP-2 against Botrytis cinerea and Fusarium oxysporum was tested in a dual culture assay in solid media, namely in a potato dextrose agar (PDA) plate. P. chrysogenum lnPP-2 was grown as described in Example 1. Botrytis cinerea and F. oxysporum were grown in PDA media at 25 °C in the dark for 5 to 10 days. A 5 mm diameter mycelial plug of P. chrysogenum lnPP-2 and another of each pathogen, taken from the edge of the fungal colonies, were placed on the opposite border of a petri dish with PDA media, approximately 5 cm away from each other. Experiments were repeated in triplicate. The plates were sealed with parafilm and incubated at 25 °C for 8 to 9 days in the dark, after which the diameter of each fungal colony was measured twice and the inhibition of the pathogen development assessed by means of the formula IG (%) = ((MDC -DP) / MDC) * 100 %, where IG denotes the inhibition of growth, MDC indicates the mean of diameters in the control and DP indicates the diameter width of the pathogen, respectively.

[0119] When the disclosed P. chrysogenum lnPP-2 was grown in co-culture with the plant pathogenic fungi, B. cinerea and F. oxysporum in solid media, a clear growth inhibition of both by P. chrysogenum lnPP-2 (Figure 2A) was observed, which was quantified as 50 and 25 %, respectively, when compared with cultures that grew on their own (Figure 2B).3. Characterisation of P. chrysogenum lnPP-2 cell-free culture filtrate.

[0120] To verify if P. chrysogenum lnPP-2 cell-free culture filtrates also have antifungal activity, filtrates were prepared. Unless otherwise stated, P. chrysogenum lnPP-2 was first grown on solid KB agar medium supplemented with half glycerol (5 mL / L) at 20 °C for 7 to 30 days. After this time, five 5-mm mycelial plugs were inoculated into 200 mL of modified KB medium (half-strength glycerol as describedabove) in a 500 mL Erlenmeyer flask. The culture was incubated at 20 °C with shaking at 160 rpm for 7 days. Under sterile conditions, the mycelial biomass was separated from the culture filtrate by decantation through a series of filters superposed from top to bottom as follows: two coffee filters, a 43-48 pm qualitative 1300 / 80 filter, a 20 pm pore filter, a 10 pm pore filter, and a 4-7 pm pore filter. All filters were placed on a funnel, and the cell-free filtrate was recovered in a clean vessel. The fungal filtrate was subsequently sterilised using 800 mL bottle-top filters (0.22 pm) and stored at 4 °C for up to 7 days.

[0121] For the scope and interpretation of the present disclosure the term "cell-free culture filtrate" or "cell-free filtrate" refers to the liquid fraction obtained from the microbial culture following removal of substantially all intact cells, cellular debris, and insoluble materials, while retaining extracellularly produced metabolites, proteins, peptides, enzymes, polysaccharides, and / or other secreted bioactive compounds. In certain embodiments, the cell-free culture filtrate comprises one or more extracellular compounds produced during growth of the microorganism under suitable culture conditions. Removal of cells may be achieved by any suitable separation technique including, but not limited to, filtration, centrifugation, sedimentation, membrane separation, or combinations thereof.

[0122] In an embodiment, the cell-free culture filtrate is subjected to sterility verification following removal of fungal biomass. Such verification may comprise plating and / or mixing aliquots of the filtrate with one or more growth media of different compositions and incubating the resulting cultures under conditions suitable for detection of microbial growth. This quality control procedure enables confirmation of the effectiveness of the biomass removal step and verification of the absence, or substantial absence, of viable microorganisms in the filtrate. In instances where fungal growth is detected, the corresponding filtrate batch may be discarded.

[0123] In an embodiment, the filtrate is substantially cell-free, preferably cell-free.

[0124] For the scope and interpretation of the present disclosure, the term "mycelial plug" refers to a portion of solid culture medium containing fungal mycelium, typically excised from an actively growing fungal colony and used as inoculum for subsequent culture propagation.

[0125] In an embodiment to evaluate the antifungal activity of P. chrysogenum lnPP-2 cell-free culture filtrate, solid plates with P. chrysogenum lnPP-2 cell-free culture filtrates were prepared as follows: culture filtrate plates (CF:PDA plates) with the same volume of cell-free culture filtrate (prepared as described in Example 3) was added to autoclaved 2xPDA media that had been allowed to cool to approximately 50 °C; Control plates (KB:PDA plates) with the same volume of KB liquid media were added to autoclaved 2xPDA media as above. The media were mixed immediately to homogenise, then poured onto 50-mm petri dishes (~10 mL / plate). In the plates containing the P. chrysogenum lnPP-2 cell-free culture filtrate, the final concentration was 50 % (v / v).

[0126] The phytopathogenic fungi and oomycetes, Botrytis cinerea, Sclerotinia trifoliorum, Penicillium expansum, Rosellinia necatrix, Fusarium oxysporum, Fusarium graminearum, Magnaporthe oryzae, Colletotrichum acutatum, Colletotrichum fioriniae, Colletotrichum nymphaeae, Stemphylium vesicarium, Alternaria brassicicola, Diaporthe amygdali, Verticillium dahlia, Pythium ultimum and Phytophthora cinnamomi were grown in PDA plates at 25 °C in the dark for 3 to 10 days, depending on the pathogen. After this time, 5 mm mycelium plugs were placed at the centre of the following plates: control KB:PDA plates and test CF:PDA plates, made as described above. The plates were incubated in the dark at 25 °C for 2 to 5 days, and growth inhibition was quantified by measuring the fungal colony diameter twice. Two replica plates were used per assay. The test revealed complete growth inhibition of B. cinerea, R. necratrix, S. trifoliorum, S. vesicarium, P. ultimum and P. cinnamomi, A. brasscicola, and D. amygdali, considerable growth reduction of P. expansum, F. oxysporum, M. oryzae, C. acutatum, and C. fioriniae, C. nymphaeae, V. dahliae, and moderate growth inhibition of F. graminearum (Figure 3 A). The growth inhibition was quantified: being close to 100 % for B. cinerea, R. necratrix, S. trifloiorum, S. vesicarium, P. ultimum and P. cinnamomi at 2 and 5 days post inoculation (dpi), 100 % for P. expansum, M. oryzae and C. acutatum at 2 dpi and 60 % for P. expansum and C. acutatum and 30 % for M. oryzae at 5 dpi, 50 and 30 % for F. oxysporum at 2 and 5 dpi, and 60 % and 45 % for C. fioriniae at 2 and 5 dpi and 25 % at 2 dpi for F. graminearum (Figure 3B).

[0127] Surprisingly, no growth inhibition of the broad-spectrum plant growth promoter, Mortierella elongata was observed (Figure 4). This data demonstrates the specificity of the antifungal activity of the P. chrysogenum lnPP-2 cell-free culture filtrate towards certain fungi and oomycetes.

[0128] In an embodiment to characterise the minimal inhibitory activity of the P. chrysogenum lnPP-2 cell-free culture filtrate, the filtrate was diluted to different concentrations and tested against Magnaporthe oryzae-G P in liquid media. M. oryzae isolate PR9 expressing the green fluorescent protein (PR9-GFP) was grown on rice flour for 3 days in the dark and 3 days under constant light (50 / 50 white light and purple light). Spores were harvested in 0.02 % (v / v) Tween-20 and counted. The assays were set-up in a black, flat-bottom 96-well plate with lxlO3spores / mL and P. chrysogenum lnPP-2 cell-free culture filtrates at different concentrations (v / v): 0 (control), 5 (P5), 10 (P10), 25 (P25), and 50 (P50) % (v / v) and the activity compared to that of Amistar Top® (1 mL / L), a commercial fungicide, in a total volume of 200 pl. Each condition was repeated in triplicate. Fluorescent readings were taken for green fluorescent protein (GFP) signal (Excitation: 479 nm, Emission: 520 nm) every 30 minutes for 72 h or 96 h at 25 °C, under continuous orbital shaking at 282 cycles per minute, using a multi-well plate reader (Agilent BioTek Synergy Hl Microplate Reader HIM).

[0129] There was concentration-dependent antifungal activity, as evidenced by reduced inhibition of M. oryzae-GFP growth at lower filtrate concentrations (Figure 5). It was observed that at 5% (v / v), thefiltrate lost its capacity to inhibit M. oryzae-GFP growth, and at 50% (v / v), its inhibitory capacity was similar to that of Amistar Top®.

[0130] In an embodiment to biochemically characterise the molecules in the P. chrysogenum lnPP-2 cell-free culture filtrate responsible for the antifungal activity, the thermal stability of the filtrate was investigated (Figure 6). For that, P. chrysogenum lnPP-2 cell-free filtrate (P50) was subjected to the following treatments before being added to M. oryzae PR9-GFP spores, incubated in liquid media and growth measured by means of fluorescence in a plate reader at 72 h post-incubation: 1) No treatment (control, P50); 2) Heated at 80 °C for 15 min; 3) Heated at 80 °C for 60 min; 4) Heated at 100 °C for 15 min; and 5) Heated at 100 °C for 60 min. The final concentration of the filtrate was 50 % (v / v; P50). The bioactivity of each filtrate was compared with that of the untreated control in inhibiting the growth of M. oryzae PR9-GFP in liquid media. It was observed that higher temperatures or longer treatment periods led to greater loss of activity, as evidenced by reduced M. oryzae-GFP growth inhibition. Surprisingly, despite a considerable reduction in activity, the culture filtrate treated at 100 °C for 60 min still retained some capacity to inhibit M. oryzae-GFP growth, suggesting that the bioactive molecules present in the disclosed cell-free filtrate have some thermal stability, a characteristic of antifungal proteins (AFPs).

[0131] In an embodiment to verify if the activity in the lnPP-2 cell-free culture filtrate could result from a protein, the filtrate was fractionated according to molecular weight. For that, microspin columns with different molecular weight (MW) cut-offs were used: 30 kDa, 10 kDa, and 3 kDa. A 500 pl volume of P. chrysogenum lnPP-2 cell-free culture filtrate was added to each size-exclusion column, and the columns were centrifuged at 14000 x g for 10 minutes. Both fractions (top and bottom) for each column were collected and placed into a new microcentrifuge tube, and the volumes were adjusted to 500 pl with 20 % (v / v) KB in water, thus obtaining 5 fractions in total: greater than 30 kDa, smaller than 30 kDa, greater than 10 kDa, smaller than 10 kDa and smaller than 3 kDa.

[0132] To test the capacity of the fractions to inhibit B. cinerea spore germination or appressorium formation in vitro, the following assays were established. Firstly, to induce sporulation, B.cinerea tagged with GFP (F29) was grown at 20 °C on V8 agar (360 mL / L V8 juice, 2 g CaCOs, 20 g / L bacteriological agar, ddHjO to 1 L) under the following conditions: photoperiod of 12 h / 12 h (dark / light) during the first 4-5 days, then placed under near-UV light for 16 h, and back to dark / light conditions for 4-5 days. When grey aerial mycelium with conidiophores and macroconidia started to fill the plate (approximately fourteen days-old fungal colonies), the spores were harvested under sterile conditions by submerging the mycelium in 1-3 mL of GB5 solution (Gamborg's medium B5, supplemented with 10 mM sucrose and 10 mM KH2PO4). The conidia were mechanically released from the agar with a cell spreader, transferred into a 2 mL centrifuge tube, and vortexed for 10 min at 2700 rpm to homogenise the suspension. The concentration of the conidia was adjusted to 2-4xl04spores mL1. Then, to assess spore germination orappressorium formation, a humidity chamber was created with two sheets of Whatman filter paper placed inside the lid of a 90 mm petri dish were soaked with 3-5 mL of autoclaved distilled water. Four to six coverslips were placed on top of the moistened filter paper, and 25 pL of spore solution was spotted onto the coverslips (500 to 1000 spores per coverslip). The same volume (25 pL) of total P. chrysogenum lnPP-2 cell-free culture filtrate, or fractions of different molecular weights or KB media (control) was spotted onto the spore drop (1:1). The petri dish was closed, sealed with parafilm, and kept at 20 °C in the dark for 7 h (for spore germination) or for 16 h (for appressorium formation), after which spore germination and hyphae development were observed under a fluorescent microscope. Approximately 25 spores were counted under a lOx microscope objective (Figure 7).

[0133] The fraction containing proteins with MWs lower than 30 kDa and higher than 10 KDa reduced spore germination, with the fraction lower than 10 kDa showing stronger activity and very close to that of the lnPP-2 cell-free culture filtrate (P50; Figure 7). The fraction higher than 10 KDa showed very little activity, indicating that the bioactive molecules are lower than 10 KDa.

[0134] In the field, the main source of infection for B. cinerea is conidia that germinate on plant surfaces and form appressorium-like structures to facilitate host infection. To investigate if the P. chrysogenum lnPP-2 cell-free culture filtrate inhibits appressorium-like structures, B. cinerea spores were incubated with culture filtrate for 16 h (Figure 8A). Only 8% of the spores treated with the culture filtrate showed appressorium-like structures (Figure 8A and 8B), suggesting that the culture filtrate may inhibit infection. It was also tested which fraction possessed this capacity to inhibit appressorium-like structure formation (Figure 8B). The experiment was performed as described above. It was observed that the activity was in fractions smaller than 10 kDa, as indicated by 28% appressorium-like structure formation in fractions smaller than 10 kDa and 20% in fractions smaller than 30 kDa. The fractions smaller than 3 kDa and larger than 10 and 30 kDa showed 84, 76, and 88% appressorium-like structure formation, respectively (Figure 8, Panel C), suggesting that the activity is not within these size ranges. Together, these data suggest that the antifungal activity is given by molecules smaller than 10 kDa, larger than 3 kDa, and highly thermally stable.

[0135] Analysis of the P. chrysogenum lnPP-2 genome revealed the presence of several AFPs, including PafB (SEQ. ID No 3) and PafC (SEQ ID No4), but not Paf. PafB has an MW of 6 kDa, is heat-stable, and is often expressed in rich media, such as KB. In an embodiment to confirm this prevalence, the bioactivity of P. chrysogenum lnPP-2 cell-free culture filtrate was compared under rich and minimal media conditions (Huber at al., 2019). The P. chrysogenum minimal media (PcMM) consisted of: 0.3 % NaNOs (w / v), 0.05 % MgSO4.7H2O (w / v), 0.05 % KCI (w / v), 0.005 % FeSO4.7H2O (w / v), 2 % D(+)-sucrose (w / v), 25 mM KPO4-buffer (pH = 5.8), and 0.1 % trace elements A (v / v). Whereas the rich media consisted of 4xPcMM. The salts added with the trace element solution were: 0.1 % FeSO4.7H2O (w / v), 0.9 % ZnSO4.7H2O (w / v), 0.04 % CuSO4.5H2O, 0.01 % MnSO4.H2O (w / v), 0.01 % H3BO3 (w / v), 0.01 %1NajMoC . HjO (w / v). The KPO4-buffer remained single-concentrated in the lx and 4x PcMM. In the PcMM media, P. chrysogenum lnPP-2 grew under the following cultivation modifications: incubation at 25 °C for 4 days with shaking at 180 rpm. P. chrysogenum lnPP-2 was grown in PcMM, 4X PcMM and KBs, and cell-free culture filtrate was prepared and tested against B. cinerea on solid media (Figure 9). P. chrysogenum lnPP-2 cell-free culture filtrate from 4xPcMM media shows greater B. cinerea inhibition than culture filtrate from PcMM, suggesting that PafB is at least in part responsible for this activity (Figure 9). Importantly, activity in KB remains higher than in 4xPcMM, which may reflect the KB medium's higher nutrient content.

[0136] 4. Antifungal activity of P. chrysogenum lnPP-2 cell-free culture filtrate on tomato infected with B. cinerea.

[0137] In an embodiment to evaluate the in planta antifungal effect of P. chrysogenum lnPP-2 cell-free culture filtrate against the virulent B. cinerea transformed with GFP (strain F29), cherry tomato leaves were used. To induce sporulation, B. cinerea-GFP was grown as described above, and spores were adjusted to lxio5spores / ml. Healthy, non-symptomatic second / third / fourth true leaves, homogeneous in colour and size, from 4- to 5-week-old cherry tomato plants were harvested and placed in a 15-cm petri dish with a few mL of distilled water. The leaves were pricked with a sterile needle at the top (adaxial) part, the equatorial part, and the left side of the midrib (ensuring that the veins and midrib remained intact). Next, the leaves were sprayed with the corresponding solution, i.e., P. chrysogenum lnPP-2 cell-free culture filtrate (50% diluted with double-distilled water), KB media (50% diluted with double-distilled water), or water control. The leaves were transferred to a Petri dish containing water agar and allowed to dry for 1-2 h under sterile conditions. Once dried, B. cinerea was inoculated by spotting 15 pL of spore suspension onto the adaxial surface of each leaf near the wound site. The petri dishes were sealed with micropore tape and transferred to a static growth chamber at 20 °C with a 12 h / 12 h photoperiod for 3 days until results were observed. Each treatment included 6 tomato leaves, photographs were taken 3 days post-infection, and the lesion area was quantified using ImageJ.

[0138] B. cinerea induces a very wide range of symptoms on host plants; on leaves, the typical symptoms are irregular, water-soaked spots that turn brown or greyish and mould can develop on both the top and bottom surfaces; on soft fruits, the most typical symptoms are soft rots, with collapsed and water soaking of parenchyma tissues, followed by the appearance of grey conidia masses. To verify if P. chrysogenum lnPP-2 cell-free culture filtrate ameliorates the leaf symptoms caused by B. cinerea, tomato leaves were sprayed with culture filtrate and infected with virulent B. cinerea-GFP spores (strain FP29; Figure 10). Culture filtrate treatment considerably reduced the spreading of B. cinerea-GFP on the leaf surface when compared to non-treated but infected control (Figure 10A, i and ii). Quantification of the lesion area showed that, on average, there was a 60% reduction in infection when leaves were treated with the culture filtrate (Figure 10B).

[0139] In an embodiment to further evaluate the in planta antifungal effect of P. chrysogenum lnPP-2 cell-free culture filtrate (P50) against the virulent B. cinerea, biological cherry tomatoes were used. Two methodologies were applied with different inoculum sources: mycelium plugs and spores. For the mycelium-mediated infection, B. cinerea was cultured on PDA agar for 5-7 days at 20 °C in the dark. Ripe tomato fruits were surface disinfected by submersion in a 1% (w / v) NaOCI solution for 1 minute, then thoroughly washed with autoclaved distilled water and left to dry naturally under sterile conditions. The fruits were dipped for 5 min in each treatment: (i) P. chrysogenum lnPP-2 cell-free culture filtrate (P100); (ii) KB media; and dried for 10 min under sterile conditions. Each tomato was pricked with a sterile needle in the upper equatorial plane to cause wounds. Then, one 5-mm B. cinerea mycelial plug, cut from the edge of the colony, was adhered to each fruit on top of the wound site. For the controls, plugs from PDA agar plates were used. The inoculated fruits were placed on individual plastic caps, which were then transferred to sterile plastic boxes containing 2-3 layers of absorbent paper at the bottom of the boxes, moistened with 15 mL of sterile distilled water to improvise a humidity chamber and facilitate infection. The boxes were incubated in a growth chamber at 20 °C with a 12 h / 12 h photoperiod. Twenty-four hours post-inoculation, mycelial and PDA plugs were removed from the inoculated fruits, and the disease was allowed to progress for an additional 3 days. For each treatment and control, three tomatoes were used, and the results were registered four days post-inoculation. Culture filtrate treatment considerably reduced the appearance of masses of grey conidia when compared with the non-treated control (Figure 11).

[0140] For the spores-mediated infection, B. cinerea-GFP (strain PF29) was grown as described above, and spore concentration was adjusted to 1x10sspores ml1. Tomato fruits were surface disinfected as described above. Each fruit was wounded 3 mm deep with a sterile syringe needle on the top equatorial plane and dipped into a 500 mL solution of each treatment for 5 minutes: (i) P. chrysogenum lnPP-2 cell-free culture filtrate (P100), (ii) KB media diluted at 20 % (v / v) with autoclaved distilled water. Then, fruits were dried for 10 min under sterile conditions to drain excess solution, after which each was transferred into transparent plastic boxes prepared as described above and placed on plastic caps for immobilisation. Approximately two hours after the treatment, each tomato was infected with 15 pL droplets of the spore suspension at 1x10sspores ml1on top of each wounding site. A 15 pL drop of Gamborg 5 solution was used as a control. The boxes were sealed with cling film and incubated at 20 °C for 4 days. Afterwards, the results were recorded, and the level of disease inhibition was quantified using ImageJ. Treatment with culture filtrate (P100) considerably reduced the appearance of grey conidial masses compared with the untreated control. Quantification of lesion sizes indicated a 59% reduction in grey mould in tomato fruits treated with the culture filtrate (Figure 12).[0014115. Purification and identification of AFPs from the P. chrysogenum lnPP-2 cell-free culture filtrates.

[0142] Antifungal proteins, also called antimicrobial proteins (AMPs), are often secreted, cysteine-rich, and positively charged. To attempt to recover AMPs from P. chrysogenum culture media, the filtrate was prepared as described above and subjected to weak cation-exchange purification, as described by Sonderegger et al. (2016). In brief, the pH of 400 mL was adjusted to 6.2 with sodium phosphate buffer (50 mM final concentration), diluted with HCI and added to an Amicon Stirred Cell ultrafiltration device (Millipore, UFSC20001) with a 30 kDa MWCO regenerated cellulose membrane (Millipore, PLTK06210).500 pL of CM Sepharose FF resin suspension (Cytiva, 17071910) was centrifuged at 700 x g for 3 min, washed twice with 2 mL of Equilibration buffer (EB; 10 mM Sodium phosphate, pH 6.2; 25 mM NaCI and 0.1 mM EDTA), and used for batch purification. For that, the stirred-cell flow-through was incubated overnight at 4 °C with gentle rotation (~15 h) on the washed CM Sepharose FF resin. The suspension was loaded onto an empty chromatographic column (Thermo Scientific Pierce, 89896) and allowed to flow by gravity. Beads were washed with 20 bead volumes of EB (5 mL), and bound proteins were eluted with 500 pL of a 10 % increment of 1 M NaCI (from 10 to 100 % (v / v)) in EB (total of 10 fractions, total volume 5 mL). Fractions were analysed by denaturing 15% SDS-PAGE and stained with Coomassie blue. For LC-MS analysis, protein bands were cut from the SDS-PAGE and sent for sequencing. For downstream analysis, protein fractions were pooled, dialysed in an excess of EB containing 20 % (v / v) glycerol, and frozen at -80 °C until further use.

[0143] The eluted fraction was run on a 15% denaturing SDS Page. A single band was observed on Coomassie Blue-stained gels across a range of salt concentrations (Figure 13 A). The band corresponding to lane 6 was excised from the SDS Page and subjected to LC-MS for protein identification. ClusterlW analysis of the identified peptides revealed homology to small, cationic, cysteine-rich antifungal proteins (AMP) produced by P. chrysogenum (Pafs): 15 peptides to PafB, one to PafC and another to a novel protein (Figure 13B). Being PafB the most abundant (Figure 13 C). This data suggests that the purified proteins correspond to at least a mixture of PafB, PafC and a novel uncharacterized protein. Analysis in SignalP 6.0 revealed that the novel uncharacterized protein has a predicted signal peptide (SEQ ID No 6 -MKLLMITTLLASLLVSTDA) with the corresponding mature form: TVVKAYKGTACKKDNYIGSVSACGSTGLSQNYKVQSLSLNFQKATASFYQQKPDRNGNCVGPRISKNSDQTCVKLPTG WDRFGCVKIHGGTC (SEQ ID No 7), containing 6 cysteines, which give rise to 3 predicted disulfide bonds, a theoretical Isoelectric point of 9.51 and a MW of 9913.25 Daltons. Considering these characteristics as hallmarks of AMPs, this novel protein is likely to correspond to a new, uncharacterized Paf and has been referred to as PafD (SEQ ID No 5).

[0144] 6. Fungicide activity of the purified P. chrysogenum PAFs in vitro and in planta

[0145] In an embodiment to confirm that the purified PAFs protein mixture (Figure 13) has antagonistic activity against different pathogens, its inhibitory activity was tested against Magnaporthe oryzae-G P (isolate PR9-GFP) using a high-throughput in vitro assay in liquid media, measured by fluorescence in amulti-well plate reader. The isolate was grown on rice flour for 3 days in the dark and 3 days under constant light (50 / 50 white light and purple light). Spores were harvested in 0.02 % (v / v) Tween-20 and counted. The assays were set up in a black, flat-bottom 96-well plate with lxlO3spores / mL and P. chrysogenum lnPP-2 cell-free culture filtrates at 50% concentration (v / v; full spectrum and fractionated under 30 kDa) were used as an internal control, as well as the purified mix of Pafs with increasing concentrations (ng) in a total volume of 100 pl per well. Each condition was repeated in quadruplicate. Fluorescent readings were taken for GFP signal (Excitation: 479 nm, Emission: 520 nm) every 60 min for 96 h at 25 °C, under continuous orbital shaking at 282 cycles per min, using a multi-well plate reader. Data were further analysed in RStudio, and percentages of M. oryzae were calculated and presented. There was concentration-dependent antifungal activity of the purified protein solution, as evidenced by an increase in the ability to inhibit M. oryzae-GFP growth with increasing protein concentrations from 238 ng to approximately 2.4 pg (Figure 14). The activity of 2.4 pg was similar to the one seen for the P. chrysogenum lnPP-2 cell-free culture filtrate at 50% (v / v), and the cell-free culture filtrate at 50% (v / v) was smaller than 30 kDa.

[0146] In an embodiment to determine that there is an activity of the purified proteins in planta, a B. cinerea-GFP (strain Cl_7) spore-mediated infection was performed in ex vivo conditions as described above. Strain Cl_7 spore concentration was adjusted to 1x10sspores ml1. Tomato fruits were surface disinfected by submersion in a 1% (w / v) NaOCI solution for 1 min, thoroughly washed with autoclaved distilled water, and left to dry naturally under sterile conditions. Each fruit was wounded 3 mm deep with a sterile syringe needle on the top equatorial plane, transferred into transparent plastic boxes and placed on top of plastic caps for immobilisation. Each tomato was further infected with a 5 pL droplet of the spore suspension at lxio6spores ml1on each wounding site. A 5 pL droplet of Gamborg 5 solution was used as a mock control. A two- to three-layer absorbent paper was previously placed at the bottom of the boxes and kept moistened with 25 mL of sterile distilled water to improvise a humidity chamber and facilitate infection. Approximately 16 h post infection (HPI; one treatment application) and 16 and 40 HPI (two treatment applications), fruits were sprayed four to five times with the treatment solutions as follows: (i) P. chrysogenum lnPP-2 cell-free culture filtrate; (ii) KB media diluted at 20 % (v / v) with autoclaved distilled water; (iii) autoclaved distilled water; and (iv) purified PAF protein mixture (PafB, PafC and PafD) at final concentration of 50 pg / mL diluted in elution buffer and water. All treatments were supplemented with 0.05% (v / v) Silwet to ensure optimal homogeneity and dispersion. Tomato fruits were left to dry for 15 min under sterile conditions to drain the excess solution after each aerosolisation. The closed boxes were incubated at 20 °C for three to four days, after which the results were recorded, and the level of disease inhibition was quantified with ImageJ.

[0147] When the treatment was applied once, there were decreases in infection of 19% and 35% with the protein mixture and the culture filtrate, respectively (Figure 15). After a single treatment, thepercentages of inhibition increased to 38% and 70%, respectively. These data indicate that the purified PAF proteins mixture is responsible for the bioactivity observed in the lnPP-2 cell-free culture filtrate against plant pathogens.

[0148] 7. Heterologous expression and production of recombinant PafB, PafC and PafD

[0149] Proteins PafB, PafC and PafD may be produced in a heterologous expression system for recombinant production, purification, and evaluation of biological activity. In an embodiment, nucleic acid sequences encoding the mature forms of PafB, PafC and PafD are individually cloned into recombinant expression constructs comprising regulatory sequences suitable for expression in heterologous host cells.

[0150] In an embodiment, the heterologous host cell is a yeast or bacterial host, including but not limited to Pichia pastoris or Bacillus subtilis. By way of example, nucleic acid sequences encoding the mature forms of PafB, PafC and / or PafD may be cloned into a yeast expression vector, such as pGAPaZA (Thermo Fisher Scientific), for expression in P. pastoris, or into a bacterial secretion vector suitable for expression in B. subtilis. The recombinant constructs may be introduced into the selected host cell according to standard transformation protocols, and transformed cells may be selected under appropriate selective conditions. The transformed host cells may be cultured under conditions suitable for recombinant expression and, in certain embodiments, secretion of proteins PafB, PafC and PafD into the culture medium. Culture supernatants or cell lysates may subsequently be collected, and the recombinant proteins may be isolated and purified by conventional methods, including affinity chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, or sizeexclusion chromatography.

[0151] The recombinant proteins thus obtained may be used directly or formulated into compositions and may be evaluated in the biological assays described herein. In certain embodiments, the recombinant proteins retain, wholly or partially, the biological activity of the corresponding native proteins, including antifungal, antimicrobial, or plant-protective activity. Biologically active variants, fragments, homologues, fusion proteins, and derivatives of proteins PafB, PafC and PafD produced in heterologous host cells are likewise contemplated within the scope of the invention.

[0152] 8. Effect of P. chrysogenum lnPP-2 cell-free culture filtrate application on the soil microbiome.

[0153] Given the broad-spectrum fungicidal activity of P. chrysogenum lnPP-2 cell-free culture filtrate, it was investigated whether it has any detrimental effects on the soil microbiome. For that, soil was obtained from 6 tomato-producing parcels. Three replicate vases for each soil origin were set up (total n = 18), containing 90-95 g of soil and arranged in a checkered pattern in 40-vase trays (5 x 8 configuration). The following treatments were applied to the one replicate per soil origin (20 mL per vase): P. chrysogenum lnPP-2 cell-free culture filtrate, diluted to 50 % (v / v) with distilled water (P50);King's B media, diluted to 20 % (v / v) with distilled water; and distilled water. Immediately before and 7 days after treatment application, soil samples were collected, and DNA was extracted using the Qiagen PowerSoil kit according to the manufacturer's instructions. In addition to the 36 samples, DNA was also extracted from 5 negative water controls. PCR amplification of the V4 region from 16S and the ITS1 region from the ITS genes followed the protocol defined by the Earth Microbiome Project. Sequencing was carried out with Illumina MiSeq, producing 250 bp paired-end reads. Read quality filtering and trimming were performed before inference of Amplicon-Sequence Variants (ASVs) using the R library dada2. Forward and reverse reads were merged, followed by chimera removal, taxonomic classification, and removal of ASVs not classified as Bacteria or Fungi. Negative controls were used to identify and remove contaminant ASVs from the samples, using the R package decontam. Alpha and beta diversity analyses were performed to describe species richness and assess how the treatments affected soil microbiome composition.

[0154] Bioinformatic analysis of the ITS (for fungi) and 16S (for bacteria) marker regions shows that the culture filtrate has only a minor impact on the bacterial community composition, likely driven by the composition of the KB media (Figure 16). The effect of treatment was not statistically significant as assessed by a generalised linear model quasipoisson (p>0.05). The parcel from which the soil originated had a statistically significant effect (p<0.05) on both bacterial and fungal community composition, explaining 73%-76% of the variation. Conversely, treatment alone had a statistically significant effect on bacterial community composition and explained only 9% of the variation. Importantly, in 4 out of 6 soils, the distances between Filtrate and King's B treatments were always smaller than the distance of either to the water treatment or the TO samples, indicating that this statistically significant effect is most likely due to the impact of King's B media.

[0155] 9. In vitro inhibition of 5. cinerea growth by formulated P. chrysogenum lnPP-2 cell-free filtrate.

[0156] In an embodiment, P. chrysogenum lnPP-2 was grown in KB medium and the cell-free filtrate prepared as described above, then it was diluted with sterile water to 40% (v / v). The filtrate was subsequently formulated by adding positively charged amino acids, namely L-arginine or L-lysine, separately (not in combination) at concentrations that ranged from 25 mM to 36 mM. The formulations were filter-sterilised through a 22 pm filter and stored at 4 °C until use. To perform B. cinerea inhibition assays, the treatments were mixed with two-times-concentrated Potato Dextrose Agar (PDA) to reach final concentrations of 12.5 mM of L-arginine (A12.5), 15 mM of L-arginine (A15), 18 mM of L-arginine (A18), 12.5 mM of L-lysine (L12.5), 15 mM of L-lysine (L15), 18 mM of L-lysine (L18), and 20 % (v / v) P. chrysogenum lnPP-2 whole filtrate P20 containing 12.5 (SP20A12.5), 15 (SP20A15), or 18 mM (SP20A18) L-arginine or L-lysine (SP20L12.5; SP20L15; SP20L18). The controls consisted of adding the growth medium KB and 100 % P. chrysogenum lnPP-2 cell-free culture filtrate (P100) to PDA (1:1; v / v), respectively. A 6-day-old B. cinerea plug (0 = 5 mm) was placed in the middle of Petri dishes containingthe different formulation groups described above. Fungal growth was recorded at 3-, 6-, 12-, and 19-days post-inoculation (dpi).

[0157] The P. chrysogenum lnPP-2 cell-free culture filtrate at 50% (v / v) P50 was very effective at 3 and 6 dpi but was almost completely inactive at 19 dpi (Figure 17A.i). Accordingly, it would not be expected that the filtrate, at even lower concentrations, would inhibit the fungus. Indeed, this was confirmed by the filtrate at 20% (v / v) P20, showing reduced inhibition at 3 dpi compared to P50.

[0158] Two amino acids [L-arginine and L-lysine] tested alone at three different concentrations (12.5, 15 and 18 mM) under the same experimental conditions showed some bioactivity against B. cinerea at 3 dpi, especially at the highest concentration of 18 mM. This effect was gradually reduced over time and lost at 19 dpi (Figure 17B).

[0159] Surprisingly, however, when the P. chrysogenum lnPP-2 cell-free culture filtrate at 20 % (v / v) was formulated separately with each of the amino acids at 18 mM (SP20A18; AP20L18), almost complete growth inhibition of the B. cinerea (> 90%) was observed even up to 19 dpi. At this time point, as all components were inactive on their own, this cannot be taken as an additive effect but clearly demonstrates a surprising synergistic inhibitory effect between the filtrate and the amino acids.

[0160] 10. Characterisation of the synergistic mode of action of the P. chrysogenum lnPP-2 cell-free culture filtrate and the formulation components against B. cinerea.

[0161] In an embodiment to evaluate the effect of the lnPP-2 formulation on B. cinerea-GFP growth, the pathogen was grown on V8 agar plates for 7-20 days at 20 °C under a 12 / 12 h photoperiod with near-UV light to stimulate sporulation. The spores were collected by scraping a sterile loop into a 1.5 mL centrifuge tube containing 1 mL of autoclaved distilled water. To facilitate the spore release and solution homogenization. The conidiophores were mechanically disrupted on a turbo vortex (5 min at 24000 rpm). The solution was filtered through a 0.70 pm cell strainer, and the conidial concentration was calculated and adjusted to 2 x 105conidia / mL in a GB5 solution supplemented with 0.25% (w / v) porcine gelatine and 10 mg / mL glucose. Then, treatments which consisted of P50 as P. chrysogenum lnPP-2 filtrate, A25 as L-arginine at 50 mM, and SP30A25 as a mixture of both treatments (60% v / v aqueous preparation of P. chrysogenum lnPP-2 filtrate supplemented with L-arginine at 50 mM) were prepared, filtered, and mixed in a 1:1 ratio with the conidial suspension of the pathogen. The control consisted of 60% (v / v) KB medium prepared as described above. All treatments were incubated at 20 °C with shaking (150 rpm). For microscopy observations, 200 pL samples from each treatment were transferred to fresh 1.5 mL centrifuge tubes at 0 h and 72 h of incubation, and propidium iodide (PI) was added at 1 pg / mL. The tubes were incubated for 15 min in the dark. Propidium iodide is a membrane-impermeant red fluorescence dye that only enters cells with compromised membranes and emits a red fluorescence upon binding to DNA / RNA. After incubation, a microscopic slide was prepared with 15 pL of the sample,and the slide was observed under the microscope. Images of each treatment were taken using a green filter with peak emission at ~510 nm and a red filter with peak emission at ~617 nm. The green channel was used to observe the GFP-tagged B. cinerea, and the red channel was used to observe the PI staining of dead cells.

[0162] In the control sample, typical pathogen growth, including spore germination and hyphal development, was observed (Figure 18, a-d). When B. cinerea spores were incubated with the lnPP-2 cell-free culture filtrate formulation (SP30A25), a clear inhibition of spore germination was observed (Figure 18, n-q). Interestingly, a synergistic mode of action was observed between the formulation components, L-arginine considerably inhibits B. cinerea spore germination (Figure 18, i-m) while P. chrysogenum lnPP-2 cell-free culture filtrate primarily kills the growing mycelium, with little impact on germination (Figure 18, e-h).

[0163] 11. Inhibition of B. cinerea growth on tomato fruits by formulated P. chrysogenum lnPP-2 cell-free culture filtrate in ex vivo conditions.

[0164] In an embodiment, the pathogen B. cinerea was grown as described above, and spores were adjusted to a final concentration of 105conidia / mL prepared in a GB5 solution supplemented with 0.25% (w / v) porcine gelatine and glucose at 10 mg / mL. To prepare the formulations, the P. chrysogenum lnPP-2 cell-free culture filtrate was dried for 24 h at 45 °C in a vacuum oven to determine the dry weight per unit of volume. The powder moisture content was determined on a moisture analyser, and the absolute dry weight was calculated accordingly. To prepare a wettable powder, a selection of adjuvants was dissolved in the liquid filtrate (Table 1). The mixture was filtered (0.22 pm) and spray dried on a lab-scale Buchi B-290 mini spray dryer set at 120 °C inlet temperature, 20-30% of the maximum feed rate capacity (corresponds to 5-10 ml / min), 100% of aspiration rate, and 40-45 mm of air flow rate (473-536 L / h). The fractions of each formulation compound were determined on a w / w basis after calculating the average moisture content of the final product. Two wettable powders, named FWP_1 and FWP_2 (Table 1), were prepared to test against B. cinerea. FWP_1 was prepared by spraydrying after adding 25 mM L-arginine, 10 mM L-histidine, and 0.01% (v / v) Tween 20, as described above, and was applied at a concentration of 96.5 mg / mL in the aqueous preparation. FWP_2 was prepared similarly, with the addition of 0.1% (w / v) Trehalose and 0.1% (w / v) D-mannitol and was applied at a concentration of 109 mg / mL in the aqueous preparation. Both formulations were adjusted to reach a final concentration of 50 mg / mL of lnPP-2 cell-free culture filtrate.

[0165] In an embodiment to perform the infection and tomato treatments, fresh, undamaged, healthy cherry tomatoes of similar size, colour and ripening stage were selected, washed with bleach (5% (v / v)) for 5 min, rinsed 2-3 times in sterile distilled water, and dried. Individual sterile caps were glued to plastic boxes, and the tomatoes were placed inside with the stem side facing down and the stigma facing upwards to reduce mobility. The tomatoes were treated preventively by spraying 2 mL of the testsolution per treatment group. The groups consisted of non-infected and infected controls sprayed with sterile distilled water, a commercial chemical product, and the two WP formulations described above. The tomatoes were infected with a 5 pL drop of B. cinerea spores 2 h after the preventive treatments. An extra curative treatment was administered to all tested groups 40 h after infection. The results were recorded at 19 dpi and calculated in ImageJ using the caps diameter (35.2 mm) as a reference. Statistical analyses were performed using R version 4.3.3. Continuous variables were subjected to hypothesis testing using either One-way analysis of variance (ANOVA), Welch's ANOVA, or the Kruskal-Wallis test, based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test). For count variables, Quasi-Poisson generalised linear models were employed to compare means between treatments. Fisher's exact test was applied to test significant difference between the proportions of the categories between treatments. The null hypothesis of equal means was rejected when the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

[0166] The disease incidence in the infected-control group was 100%, with 12 out of 12 replicates showing mild to severe infection symptoms typical of grey mould disease: 50% of the fruits exhibited severe infection symptoms, while 30% showed small necrotic areas in response to infection (Figure 19A.i). Surprisingly, both lnPP-2 formulations, FWP_1 and FWP_2, showed no disease incidence, providing better protection than the commercial chemical product (Switch®), a systemic and surface product specifically recommended for Botrytis spp. in tomato, which was applied according to the manufacturer's instructions at lg / L (Figure 19A.ii-iv and B). The commercial product failed to protect one-third of the total tested fruits at 19 dpi (Figure 19A.iv).

[0167] 12. Control of the damping-off caused by Pythium ultimum in Persian clover seedlings by formulated P. chrysogenum lnPP-2 cell-free culture filtrate in semi-controlled open-field conditions.

[0168] P. chrysogenum lnPP-2 cell-free culture filtrate was formulated as a wettable powder, named FWP_3, to test against P. ultimum. Formulation FWP_3 was prepared by spray-drying, as described above (Example 11), with 25 mM L-arginine, 10 mM L-histidine, 0.5% Trehalose (w / v), and 0.5% D-mannitol (w / v) and was applied at a concentration of 1.325 mg / mL in the aqueous preparation. The formulation was adjusted to reach a final concentration of 0.5 mg / mL of P. chrysogenum lnPP-2 cell-free culture filtrate. The P. ultimum inoculum was prepared using organic millet as a carrier substrate. The millet was placed in autoclavable flasks, submerged in water, and allowed to hydrate overnight at room temperature. The water excess was removed, and the millet was sterilised by autoclaving. After cooling to room temperature, the sterile millet was inoculated with P. ultimum agar plugs containing actively growing mycelium and incubated in darkness at 25 °C for 2 weeks to allow complete colonisation. During this period, the flasks were gently shaken every four days to ensure uniform fungal growth. Commercial substrate ("Siro Relva") was used as the plant growth medium. The P. u / t / mum-inoculatedmillet was added at 1% (w / w) to 2.5 kg of substrate, and the mixture was mixed thoroughly. The infected mix was later placed on top of 2.5 kg of non-infected substrate, bringing the total per pot to 5 kg. The substrate infection was performed one treatment at a time. Each treatment had three biological replicates. All treatments were applied before sowing, using the same total of 750 mL per pot to reach field capacity, as follows: for the non-infected and infected controls, with water; and for the commercial product Rival®, an aqueous preparation of 0.6 mL / L. The test treatment, formulation FWP_3, was applied at 1.325 mg / mL of aqueous preparation. After applying all treatments, Persian clover (Trifolium resupinatum) variety "Resal" seeds were sown directly into the pots (2 g of seeds per pot; ~460 seeds per row) in three equidistant rows to ensure uniformity and reduce spatial bias whilst simulating fieldlike conditions. Plants were maintained in a controlled growth chamber under the following environmental conditions: 14 °C during the day, 9 °C at night, a 16-hour light / 8-hour dark photoperiod, and 100% relative humidity (with dew mist) to stimulate pathogen infection. Afterwards, the plants were moved to an open tunnel outside to simulate open field-like conditions and were monitored regularly.

[0169] In an embodiment to evaluate the efficacy of the formulation, FWP_3 was compared with the commercial reference product (Rival®) under P. ultimum infection. Both treatment groups were applied preventively, immediately after the substrate infection and before seed sowing. Plant emergence was assessed 3 days after germination as an indicator of damping-off in clover, a primary symptom of P. ultimum infection. Emergence was determined by counting all emerged plants per biological replicate. Seedlings were considered emerged when cotyledons were fully expanded and exhibited normal plant vigour. A second treatment with FWP_3 was applied a week after sowing, while the commercial product (Rival®) was applied only once, as described above.

[0170] A quantitative evaluation of disease progression was carried out during the second, third, and fourth weeks of plant growth and development. The assessment focused on two main symptoms associated with P. ultimum infection: plant height and plant colour. Due to high disease pressure, plants within the same biological replicate showed considerable variability in growth. Accordingly, a structured sampling approach was implemented to ensure that the recorded measurements were representative of the overall plant population within each biological replicate. In this regard, for assessing plant symptoms, each pot contained three equidistant rows of plants. To obtain representative measurements, each row was divided into six equal sections. Within each section, the most dominant plant height and plant colour were visually determined and recorded.

[0171] In an embodiment, plant height was scored using the following scale: score 1 - Plants with height equal to or greater than the non-infected control; score 2 - Plants of intermediate height, between score 1 and score 3; score 3 - plants shorter than the intermediate range; and score 4 - dead plants.

[0172] In an embodiment, plant colour was scored as follows: score 1 - green plants comparable to the non-infected control; score 2 - plants with less than 50% of the assessed area showing chlorophyll deficiency and / or anthocyanin accumulation; score 3 - plants with more than 50% of the assessed area showing chlorophyll deficiency and / or anthocyanin accumulation and score 4 - dead plants.

[0173] For each biological replicate (i.e. pot), all scores obtained from the individual sections (across all rows) were averaged to provide a single value per time point for each parameter (i.e. plant height and colour). These average values were then used to calculate the Area Under the Disease Progress Curve (AUDPC) over time. The AUDPC integrates disease severity across the assessment period into a single value, with higher values indicating faster, more severe disease progression.

[0174] At the end of the experiment, pigment-related parameters were measured using wavelength ratios obtained from fluorescence or transmission signals. Anthocyanin content was estimated using the ratio F660 / F525, where the signal at 525 nm reflects anthocyanin levels and the signal at 660 nm is used as a reference. Flavonol content was estimated using the ratio F660 / F325, where 325 nm corresponds to flavonol-related signals and 660 nm again serves as a reference. Chlorophyll content was determined using the Chlorophyll Content Index (CCI), calculated as T931 / T635, where 635 nm corresponds to chlorophyll absorption and 931 nm is used as a reference wavelength. These ratios allow normalisation of the measurements, reducing variability caused by differences in leaf thickness or measurement conditions. Then, the plant biomass was evaluated by measuring fresh weight with plants harvested by cutting at ground level. Statistical analyses were performed using R version 4.3.2. Continuous variables were subjected to hypothesis testing using either One-way analysis of variance (ANOVA), Welch's ANOVA, or the Kruskal-Wallis test, based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test). For count variables, Quasi-Poisson generalised linear models were employed to compare means between treatments. The null hypothesis of equal means was rejected when the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

[0175] Application of FWP_3 formulation resulted in highly significant differences in Persian clover seedling emergence compared with both the infected, untreated control and the commercial product (Figure 20A). The Persian clover seedlings' emergence rate was almost 4 times higher than the nontreated infected control (Figure 20 B), corresponding to almost 64% increase (Figure 20 C). Furthermore, the emergence rate of Persian clover plants treated with the FWP_3 formulation was 10% better than that of the commercial chemical product Rival® which was applied at the same time point at a concentration of 0.6 mL / L (Figure 20 C). This increase in Persian clover plant emergence is a direct indicator to the effectiveness of FWP_3 to reduce the damping-off symptoms of P. ultimum. This result was also confirmed by the AUDPC analysis, which showed a decrease of total disease symptoms at theend of the experiment by 46.5%, which was not statistically different from the chemical Rival® that resulted in 63.2% treatment efficiency (Figure 21A and B).

[0176] The efficiency of treatments of Persian clover plants with the FWP_3 formulation and the commercial product to control P. ultimum resulted in a significant increase in the final fresh / dry weight by 4 and 7 folds, respectively, compared to the infected control (Figure 22A- D). Plants treated with the FWP_3 formulation exhibited a 26% decrease in anthocyanin content relative to the P. u / timum-infected substrate, indicating a strong mitigation of the stress symptoms associated with the pathogen's presence and accumulation (Figure 23A and B). In contrast, plants treated with the commercial product showed a 5% increase in anthocyanin content relative to the infected control, suggesting a comparatively lower capacity to alleviate stress under the same conditions.

[0177] Anthocyanin accumulation is a well-established indicator of plant stress; therefore, the observed reduction in anthocyanin levels in formulation-treated plants (FWP_3) reflects improved physiological status and enhanced tolerance to pathogen-induced stress.

[0178] Moreover, plants treated with the formulation FWP_3 showed statistically significant higher flavonol accumulation and higher chlorophyll contents (Figure 23C- F) compared to the commercial reference product Rival® under P. ultimum infection conditions. These results indicate an enhanced plant defence response together with improved maintenance of photosynthetic function under pathogen pressure. The observed effect demonstrates that the formulation FWP_3 not only reduces disease severity but also supports improved physiological performance in treated plants, thereby providing an advantage over existing commercial solutions.

[0179] 13. Control of broccoli black spot disease caused by Alternaria brassicicola by formulated P. chrysogenum lnPP-2 cell-free culture filtrate.

[0180] Broccoli (Brassica oleracea) variety "Ramoso Calabrese" seeds were germinated in alveolar trays containing a commercial substrate ("SIRO® Germinagao Bio"). Seedlings were cultivated under semicontrolled greenhouse conditions (20-22°C and approximately 80% relative humidity) and transplanted two weeks after emergence into 0.70 L pots. Plants were maintained under the same environmental conditions for five to six weeks, until they reached the phenological stage with five fully developed leaves, at which point they were subjected to different treatments and infected with spores of A. brassicicola.

[0181] In an embodiment, the fungal pathogen A. brassicicola was cultured on PDA medium supplemented with streptomycin (60 pg / mL) to inhibit bacterial contamination at approximately 22 °C and in darkness for 10-12 days to induce sporulation. Spores were harvested and suspended in sterile distilled water to obtain a final concentration of approximately 1 x 105spores / mL. The surfactant Silwet® was added to the suspension at a final concentration of 0.02% (v / v) to promote uniformdistribution and adhesion of spores to leaf surfaces. To assess the efficacy of lnPP-2 cell-free culture filtrate against the black spot disease of broccoli, two wettable powders were produced by spray drying lnPP-2 cell-free culture filtrate. For the first, the lnPP2 cell-free culture filtrate was supplemented with 25 mM L-arginine, 10 mM L-histidine, 0.1% (w / v) Trehalose, 0.1% (w / v) D-mannitol, 0.5% (w / v) of quaternized water-soluble chitosan, and 0.01% (v / v) Tween 20 (FWP_4). While the second consisted in the same combination without the components Trehalose and D-mannitol (FWP_4.1). FWP_4 was tested first and was applied at 59 mg / mL of aqueous preparation, yielding a final concentration of 20 mg / mL of lnPP-2 filtrate. The treatment was compared to an untreated non-infected control and a control under A. brassicicola infection.

[0182] In another embodiment, the second formulation FWP_4.1 was applied at almost double the rate of FWP_4 to reach 40 mg / mL of lnPP-2 filtrate and was compared with the commercial reference products Dagonis® and Ortiva Top®, applied at 2 mL / L and 5 mL / L, respectively, following the manufacturer's instructions.

[0183] The preventive efficacy of FWP_4 and FWP_4.1 formulation treatments were evaluated by spraying prior to plant infection with the pathogen. One day before infection, each broccoli leaf was sprayed with the FWP_4 / FWP_4.1 formulation using an airbrush connected to a compressor (pressure: 4 bars; nozzle diameter: 0.5 mm), delivering approximately 8 mL per leaf. Control plants were treated with sterile distilled water. Treated plants were maintained under controlled conditions for 24 h in a growth chamber with a photoperiod of 16 h light at a temperature of 25 °C and 8 h in the dark at a temperature of 22 °C with 80% relative humidity to allow the treatment's absorption. Following the pretreatment period, plants were infected with a prepared spore suspension (1 x 105spores / mL) by spraying each leaf with an airbrush, delivering approximately 8 mL per plant to ensure uniform coverage of the upper leaf surfaces. Plants were incubated in darkness under dew conditions (100% relative humidity) for 24 h to promote spore germination and infection and subsequently transferred to a controlled growth chamber (25 °C Day / 22 °C night; 16 h photoperiod; 80% relative humidity) to allow disease development for six to seven days. Plants were monitored for symptom development, which appeared following the dew incubation period and progressed over the subsequent days. Disease severity was assessed at 7 days post-infection (7 dpi) based on symptom development following pathogen inoculation, using a protocol adapted from Macioszek et al. (2018). Three principal symptoms associated with infection were initially evaluated: (i) Alternaria lesion diameter, (ii) leaf chlorosis, and (iii) spatial distribution of Alternaria lesions across the leaf surface. Each parameter was scored using a standardised five-class ordinal scale representing increasing levels of severity. To determine the most robust and analytically suitable parameter for quantifying disease severity, correlation analyses were performed across five independent experiments. These analyses revealed a strong positive correlation between lesion distribution and lesion diameter (Spearman's p ~ 0.8), demonstrating that lesiondistribution alone constitutes a reliable and accurate proxy for overall disease severity. Accordingly, lesion distribution was selected as the primary parameter for subsequent assessments of disease severity. Lesion distribution reflects the extent of Alternaria-induced lesion coverage across the leaf surface and was quantified as the percentage of affected leaf area. This parameter was classified into five severity categories as follows: (1) no visible lesions; (2) less than 25% of the leaf surface covered by lesions; (3) 25-50% coverage; (4) greater than 50% coverage; and (5) complete or near-complete coverage resulting in leaf necrosis or death. The reduction to a single parameter improved scoring consistency, reduced observer-dependent variability, and maintained the discriminatory capacity of the original multi-parameter framework, while enhancing robustness for statistical analysis. For quantitative evaluation, categorical scores were converted to their corresponding class midpoints, thereby enabling treatment comparisons using continuous variables. Each leaf from three plants per treatment was individually evaluated and assigned to one of the five lesion distribution classes. Statistical analyses were performed using R version 4.3.3. Continuous variables were subjected to hypothesis testing using either One-way analysis of variance (ANOVA), Welch's ANOVA, or the Kruskal-Wallis test, based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test). For count variables, Quasi-Poisson generalised linear models were employed to compare means between treatments. Fisher's exact test was applied to test significant difference between the proportions of the categories between treatments. The null hypothesis of equal means was rejected when the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

[0184] The first test showed that plants treated with the FWP_4 formulation consistently reduced the disease severity relative to the infected control. FWP_4 treatment resulted in a 66% average reduction in disease severity relative to the infected control, indicating a strong capacity to limit the pathogen development under the tested conditions (Figure 24A and B).

[0185] FWP_4.1 also reduced the disease severity of A. brassicicola infected broccoli leaves by 52%. This reduction was not statistically different from the two commercial chemical products tested in the experiment (Figure 24C and D). Ortiva Top® and Dagonis® yielded 90% and 97% of disease control, respectively, when applied at the manufacturers' highest recommended doses. This shows the potential of FWP_4.1 to provide environmentally friendly solutions to control fungal diseases with treatment efficiencies that could compete with the best chemicals in the market.

[0186] 14. Control of rice blast disease caused by Magnaporthe oryzae by formulated P. chrysoqenum lnPP-2 cell-free culture filtrate.

[0187] A wettable powder of lnPP-2 cell-free culture filtrate was developed and named FWP_5. FWP_5 consists of a spray-dried solution of lnPP-2 cell-free culture filtrate containing 25 mM L-arginine, 10 mM L-histidine, 1% (w / v) Trehalose, 1% (w / v) D-mannitol, and 0.01% (v / v) Tween 20.

[0188] The Rice (Oryza sativa) cultivar "Bomba / ' known to be susceptible to M. oryzae isolate Guyll, was used in this study. Bomba seeds were sown in a commercial substrate ("SIRO® Germinagao Bio"), and plants were grown under controlled conditions in a growth chamber (22-24 °C, approximately 80% relative humidity, 16 h light / 8 h dark photoperiod). Plants were infected at the vegetative stage, approximately two to three weeks after sowing. Each experimental unit consisted of one pot containing six plants, and a total of eighteen pots were included in the experiment.

[0189] The fungal pathogen M. oryzae (strain Guyll, subculture 1) was used for infection. Cultures were initiated from glycerol or filter paper stocks and grown on complete medium (CM) or rice flour agar (RF) plates and incubated at 24-25 °C under controlled photoperiod conditions (12 h light / 12 h dark or continuous light, depending on the experimental batch) for 7-10 days. Actively growing mycelium (approximately 2 mm2) from colony margins was subcultured onto fresh plates and incubated for an additional 7-14 days under the same conditions to promote sporulation. To induce conidiation, aerial hyphae were gently removed from 7-day-old cultures using a sterile loop or brush, and the cultures were then incubated for an additional 1-2 days. Conidia were harvested by adding 500-1000 pL of sterile distilled water or 0.02% (v / v) Tween-20 to the culture surface and gently scraping with an L-shaped spreader. The conidia suspension was transferred to sterile tubes and, where necessary, filtered through sterile gauze or a 70 pm cell strainer to remove mycelial debris. The filtrate was centrifuged for approximately 5 min at 8000 x g, the supernatant discarded, and the pellet resuspended in sterile distilled water or 0.02% (v / v) Tween-20. Conidial concentration determined was adjusted to approximately 1 x 105conidia / mL in a solution containing 0.02% (v / v) Tween-20 and 0.25% porcine-derived gelatin (v / v) to enhance adhesion to leaf surfaces.

[0190] In an embodiment to evaluate the treatment efficacy, control plants were first mock-treated with a solution of sterile distilled water containing 0.02% (v / v) Tween-20 and 0.25% (v / v) gelatin, without conidia. Treatments were subsequently applied using an airbrush system equipped with a 0.5 mm nozzle connected to a compressor operating at 4 bars. Twenty-four hours after treatment application, plants were infected with 2 mL of conidial suspension (1 x 105conidia / mL) per pot, using the same airbrush conditions. The suspension was applied from approximately 30-40 cm, and pots were rotated during spraying to ensure homogeneous application and uniform coverage of all aerial tissues.

[0191] Immediately after infection, plants were incubated under dew conditions (100% relative humidity, 25 °C, in darkness) for 24 h to promote infection. Thereafter, plants were transferred to a controlled growth chamber set to a 16 h light / 8 h dark photoperiod, 25 °C, and approximately 95% relative humidity, with the light source positioned approximately 50 cm above the plants. Plants were maintained under these conditions for six days to allow symptom development. Disease severity was assessed at 7 days post-infection (7 dpi) using a disease index scale adapted from Hensawang et al. (2017) and modified to increase sensitivity and robustness for quantitative analysis under ourexperimental conditions. The original scale comprised six severity classes defined by qualitative descriptors of lesion characteristics and distribution. However, preliminary analyses conducted across five independent experiments revealed an almost perfect correlation between lesion distribution and lesion diameter (Spearman's p ~ 1), indicating that lesion diameter alone provided an accurate and sufficient quantitative proxy for disease severity. Based on this observation, the scale was simplified and readapted to include four severity classes defined exclusively by lesion distribution. This reduction in the number of categories improved scoring consistency, reduced observer subjectivity, and maintained the original scale's discriminatory capacity while enhancing its suitability for quantitative analysis. All leaves from the 12 plants per treatment were evaluated individually and assigned to one of four severity classes based on lesion diameter. To enable quantitative statistical analysis and facilitate biologically meaningful comparisons among treatments, each categorical class was converted to its corresponding midpoint value (Willocquet et al., 2023), representing the central lesion distribution of that class. These midpoint values were subsequently used as continuous variables for downstream statistical analyses of disease severity. Statistical analyses were performed using R version 4.3.3. Continuous variables were subjected to hypothesis testing using either One-way analysis of variance (ANOVA), Welch's ANOVA, or the Kruskal-Wallis test, based on the assumptions of normality (Shapiro's test) and heteroscedasticity (Levene's test). For count variables, Quasi-Poisson generalised linear models were employed to compare means between treatments. Fisher's exact test was applied to test significant difference between the proportions of the categories between treatments. The null hypothesis of equal means was rejected when the p-values were below the significance thresholds: • p-value < 0.10, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

[0192] In an embodiment, the formulation FWP_5 significantly decreased disease incidence relative to the infected untreated control, with efficacy similar to that of a commercial chemical product (Figure 25). Plants infected with the pathogen exhibited a mean disease severity of 40%, whereas formulation treatment reduced it to approximately 20%, corresponding to a 50% decrease in symptom development (Figure 25B). This reduction was statistically significant (Figure 25A).

[0193] Importantly, the disease suppression level achieved with the formulation (FWP_5) was comparable to that obtained with the commercial product (Amistar®), which showed a similar range of disease severity values and was not statistically different from the formulation treatment group. Both treatments significantly reduced disease severity compared to the untreated infected control.

[0194] The term 'comprising', whenever used in this document, is intended to indicate the presence of stated features, integers, steps, or components, but not to preclude the presence or addition of one or more other features, integers, steps, components, or groups thereof.

[0195] The terms "comprising", "comprises" and "comprised of" as used herein are synonymous with "including", "includes" or "containing", "contains", and are inclusive or open-ended and do not excludeadditional, non-recited members, elements or method steps. The terms also encompass "consisting of" and "consisting essentially of", which enjoy well-established meanings in patent terminology.

[0196] All references recited in this document are incorporated herein in their entirety by reference, as if each and every reference had been incorporated by reference individually.

[0197] Those skilled in the art will recognise or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description but rather is as set forth in the appended claims.

[0198] Where singular forms of elements or features are used in the specification of the claims, the plural form is also included, and vice versa, if not specifically excluded. For example, the term 'a fungus' or 'the fungi1also includes the plural forms 'fungi' or 'the fungi', and vice versa. In the claims, articles such as 'a', 'an', and 'the' may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include 'or' between one or more members of a group are considered satisfied if one, more than one, or all the group members are present in, employed in or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in or otherwise relevant to a given product or process. The invention also included embodiments in which more than one, or all, of the group members are present in, employed in, or otherwise relevant to a given product or process.

[0199] Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims or from relevant portions of the description are introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, when the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

[0200] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and / or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwiseindicated or otherwise evident from the context and / or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

[0201] In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or all of the claims. Where ranges are given, any value within the range may be explicitly excluded from any one or all of the claims. Any embodiment, element, feature, application, or aspect of the compositions and / or uses and methods of the invention can be excluded from any one or more of the claims. For purposes of brevity, all embodiments in which one or more elements, features, purposes, or aspects are excluded are not set out forth explicitly herein.

[0202] The above-described embodiments are combinable.

[0203] The Form RO / 134, filed together with the Application as filed, is part of the Description.

[0204] The following claims further set out particular embodiments of the disclosure.Sequence List:Seq. ID Sequence Molecule QualifierOrganism name ResiduesNo name type Molecule Type1 Penicillium Penicillium DNA genomic DNA ctgggtcacctcccacccgtgtttattttaccttgt chrysogenum chrysogenum tgcttcggcgggcccgccttaactggccgccggg lnPP-2 ITS gggcttacgcccccgggcccgcgcccgccgaag sequence acaccctcgaactctgtctgaagattgtagtctg agtgaaaatataaattatttaaaactttcaacaa cggatctcttggttccggcatcgatgaagaacgc agcgaaatgcgatacgtaatgtgaattgcaaatt cagtgaatcatcgagtctttgaacgcacattgcg ccccctggtattccggggggcatgcctgtccgag cgtcattgctgccctcaagcacggcttgtgtgttg ggccccgtcctccgatcccgggggacgggcccg aaaggcagcggcggcaccgcgtccggtcctcga gcgtatggggctttgtcacccgctctgtaggccc ggccggcgcttgccgatcaacccaaatttttatc caggttgacctcggatcaggtagggatacccgct gaacttaagcatatcaataagcggaggaa 2 Penicillium Penicillium DNA genomic DNA ATGCGTGAGATTGTACGTGATCCCCT chrysogenum chrysogenum CCAGACGCGTCTTTTGTTTTCATATGG lnPP-2 CCCCTGAGCCACGACCCCACTCCCAA complete CAG ATCTTTTG CTAACTTG CTCTAG GT beta-tubulin TCACCTCCAAACCGGCCAGTGTGTAA gene GTTCGACATGGAACATTCTTGGAAAC sequence ATTCTTCGATGCGTGGGACTAAACTG G AATTG G GTTATAG G GTAACCAAATTGGTGCCGC H I LI GGTAAGTCTCGGAGC 1 1 1 1 1 1 1 1 CGCGTTGGGTATCAATT GACAAGTTGCTAACTGGATTACAGGC AAACCATCTCTG GCGAGCACGGTCTC GATGGCGATGGACAGTAAGTTTAAC AGTGATGGGGATTCTGGTGGATCAC ACGTCTG ATATCTTG CTAG GTACAAT GGTACCTCCGACCTCCAGCTCGAGCG TATGAACGTCTACTTCAACCATGTGA GTACAATGACTGGGAATCTTAATTGT GCATCATCTGATCGGGCG 1 1 1 1 1 CTTT GACAATCTAGGCCAGCGGTGACAAG TACGTTCCCCGTGCCGTTCTGGTCGA TTTGGAGCCCGGTACCATGGACGCTG TCCGCTCCGGTCCCTTCGGCAAGCTT TTCCGCCCCGACAACTTCGTCTTCGGT CAGTCCG GTG CTG GTAACAACTG G G CTAAGGGTCACTACACTGAGGGTGCC GAG CTTGTTG ACCAG GTCCTCG ATGT CGTCCGCCGTGAGGCCGAGGGCTGT GACTGCCTCCAGGGTTTCCAGATCAC CCACTCCCTGGGTGGTGGTACCGGTG CCGGTATGGGTACACTCCTGATCTCC AAG ATCCGTG AG G AGTTCCCCG ACC GTATGATGGCCACTTTCTCCGTCGTC CCCTCCCCCAAG GTCTCCG ACACCGT TGTTGAGCCTTACAACGCTACCCTCTC CGTCCACCAG CTTGTTG AG C ACTCTG ACGAGACTTTCTGTATCGATAACGAG GTATGAAACGCGGGGAAATACTGAC GTGAAGAATACTGACAATATTAGGCT CTCTACG ACATTTG CATG CGTACCCTC AAGCTCCCCCAGCCTTCCTACGGTGA CCTGAACCACCTCGTCTCCGCCGTCAT GTCCGGTGTGACCACCTCCCTTCGTTT CCCCGGTCAGCTCAACTCCGATCTTC GCAAGCTCGCCGTCAACATGGTTCCC TTCCCTCGTCTG CACTTCTTCATG GTC GGCTTCGCTCCCCTGACCAGCCGTGG TG G CTACTCTTACCG CCAG GTCAACG TCCCCGAGTTGACCCAGCAGATGTTC GACCCCAAGAACATGATGGCTGCCTC CGACTTCCGTAATGGCCGCTACCTCA CTTG CTCCG CTCTGTTCCG CG GTAAG GTCTCCATGAAGGAGGTTGAGGACC AGATGCGCAACATCCAGAACAAGAA CCAGAGCTACTTCGTTGAGTGGATCC CCAACAACGTCCAGACCGCTCTGTGC TCCGTTCCCCCCCGTGGCCTCAAGAT GTCTTCCACCTTCGTCGGTAACTCGAC TTCCATCCAGGAGCTCTTCAAGCGTGTCGGCGACCAGTTCACTGCCATGTTCCGTCG CA AG G CTTTCTTG C ACTG GTA CACTGGTGAGGGTATGGACGAGATG GAGTTCACTGAGGCTGAGAGCAACA TGAACGATCTTGTCTCCGAGTACCAG CAATACCAG G AGG CCTCCGTCTCCG A GGGCGAGGAGGAGTAGTAAGGATTC CCCACATCACCCGGCTTTCGAATATAT CGACTAACGAATTCTCCCCCTAI I l l i AGCCTCGCTGAGGACATTGTTGACGA GGAGGTTTAA3 Penicillium Penicillium AA protein MHITSIAIVFFAAMGAVASPIATESDDL chrysogenum chrysogenum DARDVQLSKFGGECSLKHNTCTYLKGG lnPP-2 PafB KNHVVNCGSAANKKCKSDRHHCEYDE protein HHKRVDCQTPVsequence4 Penicillium Penicillium AA protein MKVTALLFTLMAATAVSASVLDTRDTC chrysogenum chrysogenum GGGYGVDQRRTNSPCQASNGDRHFC lnPP-2 PafC GCDRTGIVECKGGKWTEIQDCGGASC protein RGVSQGGARCsequence5 Penicillium Penicillium AA protein MKLLMITTLLASLLVSTDATVVKAYKGT chrysogenum chrysogenum ACKKDNYIGSVSACGSTGLSQNYKVQS lnPP-2 PafD LSLNFQKATASFYQQKPDRNGNCVGP protein RISKNSDQTCVKLPTGWDRFGCVKIHG sequence GTC6 predicted Penicillium AA protein MKLLMITTLLASLLVSTDA signal peptide chrysogenum7 mature form Penicillium AA protein TVVKAYKGTACKKDNYIGSVSACGSTG chrysogenum LSQNYKVQSLSLNFQKATASFYQQKPDRNGNCVGPRISKNSDQTCVKLPTGWDRFGCVKIHGGTCReferencesBugeda, A., Garrigues, S., Gandi'a, M., Manzanares, P., Marcos, J.F. & Coca, M. (2020) Antifungal Protein AfpB Induces Regulated Cell Death in its Parental Fungus Penicillium digitatum. Applied and Environmental Science, 5(4), e00595-20.Garrigues, S., Gandi'a, M., Popa, C., Borics, A., Marx, F., Coca, M., Marcos, J.F. & Manzanares, P. (2017) Efficient production and characterization of the novel and highly active antifungal protein AfpB from Penicillium digitatum. Scientific Reports, 7:14633.Hensawang S, Wangwongchai A, Humphries U, Bunsri T (2017) Simulation of severity of rice blast disease in Prachin Buri using plant disease epidemiological model: simulation of rice blast disease. The 22nd Annual Meeting in Mathematics (AMM 2017), Department of Mathematics, Faculty of Science, Chiang Mai University, Chiang Mai, ThailandHuber, A., Lerchster, H., & Marx, F. (2019). Nutrient Excess Triggers the Expression of the Penicillium chrysogenum Antifungal Protein PAFB. Microorganisms, 7(12), 654.Kaiserer, L., Oberparleiter, C., Weiler-Gorz, R., Burgstaller, W., Leiter, E. & Marx, F. (2003) Characterization of the Penicillium chrysogenum antifungal protein PAF. Arch. Microbiol., 180, 204-210. Karpova, N.V., Yaderets, V.V., Glagoleva, E.V., Petrova, K.S., Ovchinnikov, A.L & Dzhavakhiya, V.V. (2021) Antifungal Activity of the Dry Biomass of Penicillium chrysogenum F-24-28 and its Application in Combination with Azoxystrobin for Efficient Crop Protection. Agriculture, 11, 93.Macioszek, V.K., Lawrence, C.B. and Kononowicz, A.K. (2018). Infection cycle of Alternaria brassicicola on Brassica oleracea leaves under growth room conditions. Plant Pathol., 67: 1088-1096.Manzanares, P., Garrigues, S., Gandi'a, M. & Marcos, J.F. Anti-fungal protein and uses thereof. (2019a) WO2019 / 234280 Al.Manzanares, P., Garrigues, S., Gandi'a, M., Marcos, J.F. & Coca, M. (2019b) Methods for the biological control of infections caused by phytopathogens in plants and crops, by means of the administration of the protein afpa from the fungus penicillium expansum. WO2019 / 243652 Al.Sonderegger C, Galgoczy L, Garrigues S, Fizil A, Borics A, Manzanares P, Hegedus N, Huber A, Marcos JF, Batta G, & Marx F. (2016) A Penicillium chrysogenum-based expression system for the production of small, cysteine-rich antifungal proteins for structural and functional analyses. Microbial Cell Factories 15:192.Willocquet L., Savary S., Singh K. P. (2023). Revisiting the use of disease index and of disease scores in plant pathology. Indian Phytopathol. 76, 909-914.(Original in Electronic Form)(This sheet is not part of and does not count as a sheet of the international application)0-1 Form PCT / RO / 134Indications Relating to DepositedMicroorganism(s) or Other BiologicalMaterial (PCT Rule 13bis)0-1-1 Prepared Using ePCT-FilingVersion 4.17.012 MT / FOP 20260506 / 2.80-2 International Application No.PCT / EP2026 / 0636860-3 Applicant's or agent's file reference P2230-7WO1 The indications made below relate tothe deposited microorganism(s) orother biological material referred to inthe description on:1-1 page 3 , 7 , 491-2 line 2 , 2 , 11-3 Identification of deposit1-3-1 Name of depositary institution MUM Mycotheque of the University of Minho1-3-2 Address of depositary institution MUM - Micoteca da Universidade do Minho (Fungal collection)Centro de Engenharia BiologicaUniversidade do MinhoCampus de Gualtar4710-057 BragaPortugal1-3-3 Date of deposit 08 May 2026 (08.05.2026)1-3-4 Accession Number MUM P 26.031-4 Additional Indications Penicillium chrysogenum InPP-21-5 Designated States for Which All designationsIndications are Made1-6 Separate Furnishing of IndicationsThese indications will be submitted to theInternational Bureau laterFOR RECEIVING OFFICE USE ONLY0-4 This form was received with the Yesinternational application:(yes or no)0-4-1 Authorized officer Gatinet, BrunoFOR INTERNATIONAL BUREAU USE ONLY0-5 This form was received by the international Bureau on:0-5-1 Authorized officer

Claims

C L A I M S1. Penicillium chrysogenum strain with the deposit number MUM-P 26.03 received on 8thmay 2026 at the Micoteca da Universidade do Minho.

2. Penicillium chrysogenum strain with a genome comprising:an ITS sequence comprising a sequence 90% identical to SEQ ID No 1; anda beta-tubulin gene sequence comprising a sequence 90% identical to SEQ ID No 2.

3. Penicillium chrysogenum strain wherein the Penicillium chrysogenum strain produces antifungal proteins, wherein the antifungal proteins comprise an amino acid sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, or SEQ ID No 5.

4. Penicillium chrysogenum strain according to any of the previous claims, for controlling and / or prevent plant or fruit diseases.

5. Penicillium chrysogenum strain according to the previous claim, wherein the disease is an infection, in particular a fungal infection.

6. Penicillium chrysogenum strain according to any of the previous claims 4-5, wherein the infection is caused by phytopathogenic fungi or oomycetes.

7. Penicillium chrysogenum strain according to the previous claim, wherein the infection is caused by a phytopathogenic fungi selected from: Botrytis cinerea, Sclerotinia trifoliorum, Penicillium expansum, Rosellinia necatrix, Fusarium oxysporum, Fusarium graminearum, Magnaporthe oryzae, Colletotrichum acutatum, Colletotrichum fioriniae, Colletotrichum nymphaeae, Stemphylium vesicarium, Alternaria brassicicola, Diaporthe amygdali, Verticillium dahlia, or combinations thereof; and / or an oomycete selected from Pythium ultimum, Phytophthora cinnamomi, or combinations thereof.

8. Penicillium chrysogenum strain according to any of the previous claims 4-7, wherein the infection is caused by B. cinerea.

9. Penicillium chrysogenum strain according to any of the previous claims 4-8, wherein the disease is grey mould or root rot.

10. Penicillium chrysogenum strain according to any of the previous claims 4-9, wherein the plant is tomato, vine, rice or Persian clover.

11. Filtrate obtained from the Penicillium chrysogenum strain described in any of the previous claims 1- 10, for controlling and / or prevent plant or fruit diseases, wherein the filtrate comprises one or more extracellular bioactive compounds produced by the Penicillium chrysogenum strain.

12. Filtrate according to the previous claim, wherein the filtrate is substantially free of fungal cells, mycelia, or insoluble material; preferably the filtrate is substantially cell-free; more preferably the filtrate is a cell-free filtrate.

13. Filtrate according to any of the previous claims 11-12, wherein the filtrate comprises proteins, peptides, polysaccharides, metabolites, glycoproteins, lipids, nucleic acids, or combinations thereof.

14. Filtrate according to of the previous claims 11-13, wherein the filtrate comprises one or more antifungal protein, preferably a protein with a molecular weight below 30 kDa, more preferably below 20 kDa, even more preferably a molecular weight that ranges from 3 kDa to 15 kDa.

15. Filtrate according to of the previous claims 11-14, wherein the filtrate comprises a protein selected from PafB (SEQ ID No 3), PafC (SEQ ID No 4), PafD (SEQ ID No 5), or mixtures thereof.

16. Composition for controlling and / or prevent plant or fruit diseases comprising an effective amount of the Penicillium chrysogenum strain described in any of the previous claims 1-10, and / or the filtrate described in any of the previous claims 11-15, and / or an antifungal protein wherein the protein has a sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, or SEQ ID No 5, or mixtures thereof; and a suitable additive.

17. Composition according to the previous claim, wherein the suitable additive is selected from a list consisting of: a carrier, a solvent, a buffer, a stabiliser; a preservative, an excipient, a surfactant, an adhesion agent, a drying agent, an emulsifier, an osmoprotectant, a sun protectant, a wetting agent, a stabilizer, an amino acid, an antioxidant, a chelating agent, a biopolymer, a sugar, a biosurfactant, or mixtures thereof18. Composition according to the previous claim, wherein the amino acid is selected from phenylalanine, valine, tryptophan, isoleucine, methionine, leucine, L-lysine, histidine, serine, proline, glutamine, glycine, alanine, tyrosine, L-arginine, cysteine or mixtures thereof.

19. Composition according to any of the previous claims 16-18, wherein the carrier is selected from alginate, chitosan, ulvan, fucoidan, carrageenan, xanthan gum, gellan gum, guar gum, gelatin, gum arabic, lignin, starch, maltodextrin, dextrin, cyclodextrin, dextran, zein, protamine sulphate, lecithin, gelatin, methacrylate-modified lignin, methacrylated gellan gum, polyvinyl alcohol, low density polyethylene, poly(e-caprolactone), polyethylene glycol, poly(lactic-co-glycolic acid), poly-L- lysine, their derivatives or combinations thereof; preferably chitosan, more preferably quaternized chitosan.

20. Composition according to any of the previous claims 16-19, further comprising an agriculturally acceptable compound; preferably wherein the agriculturally acceptable compound is selected from: plant strengtheners, growth promoters, biostimulants, nutrients, fertilisers, vitamins, minerals; or mixtures thereof.

21. Composition according to any of the previous claims 16-20, further comprising a biological plant protector agent selected from essential oils, microorganisms, extracts, fungi or other natural, semisynthetic or synthetic biodegradable and non-toxic biomolecules, or mixtures thereof; preferably an essential oil.

22. Composition according to any of the previous claims 16-21, comprising:10 - 99.5% (v / v) of the filtrate described in any of the previous claims 11-15, preferably 10 - 50% (v / v), more preferably 15 - 30% (v / v);12 - to 35 mM of an aminoacid, preferably 12.5 - to 20 mM of an aminoacid;preferably wherein the aminoacid is L-arginine, L-lysine, L-histidine, or combinations thereof.

23. Composition according to any of the previous claims 16-22, wherein the composition comprises 0.5 to 60 mg / mL of the filtrate described in any of the previous claims 11-15; preferably 30 - 60 mg / mL.

24. Composition according to any of the previous claims 16-23, wherein the composition comprises 20 - 80 pg / mL of the antifungal protein; preferably, 25-60 pg / mL.

25. Composition according to any of the previous claims 16-24, further comprising:0.1- 1% (w / v) of trehalose, preferably 0.2 to 0.5% (w / v);0.1 - 1% (w / v) of D-manitol, preferably 0.2 to 0.5% (w / v); and / or0.1 - 1% (w / v) of a carrier, preferably 0.2 to 0.5% (w / v), more preferably wherein the carrier is chitosan, in particular quaternized chitosan.

26. Composition according to any of the previous claims 16-25, wherein the composition is in the form of a liquid, suspension concentrate, wettable powders, granules, flowables, microencapsulations or nanoencapsulations.

27. Use of the Penicillium chrysogenum strain disclosed in any of the previous claims 1-10, the filtrate described in any of the previous claims 11-15, and / or the composition described in any of the previous claims 16-26 as a biological plant protection agent.

28. Use one or more antifungal proteins as a biological plant protection agent, wherein the one or more antifungal proteins comprise an amino acid sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, or mixtures thereof.

29. Use according to the previous claim, wherein the one or more antifungal proteins comprise at least two proteins having sequences selected from SEQ ID No 3, SEQ ID No 4, and SEQ ID No 5; preferably the one or more antifungal proteins comprise proteins having the sequences SEQ ID No 3, SEQ ID No 4, and SEQ ID No 5.

30. Use according to any of the previous claims 28 - 29, wherein the proteins are recombinant proteins.

31. Use according to any of the previous claims 27-30, wherein the plant is selected from tomato, vine, rice or Persian clover.

32. A method for control and / or prevent plant or fruit diseases, comprising applying an effective amount of the Penicillium chrysogenum strain disclosed in any of the previous claims 1-10, and / or the filtrate described in any of the previous claims 11-15, and / or one or more antifungal proteins with a sequence at least 95% identical to a sequence selected from SEQ ID No 3, SEQ ID No 4, or SEQ ID No 5, or mixtures thereof, and / or the composition described in any of the previous claims 16-26; preferably for control and / or prevent of plant diseases caused by phytopathogenic fungi and oomycetes.